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I. Introduction
The American Medical Association (AMA) and Manatt Health released a national roadmap 
in September 2019 to guide policymakers in taking action to help end the nation’s opioid 
epidemic.1 Based largely on in-depth analyses of the responses to the opioid epidemic in 
Colorado, Mississippi, North Carolina, and Pennsylvania, the 2019 roadmap identified numerous 
promising strategies as well as areas where more work and innovation clearly were required.
This expanded 2020 roadmap starts with our 2019 policy recommendations and an assessment 
of progress made. The results are mixed, with the COVID-19 pandemic creating new challenges 
but also opening up new opportunities. For example, the important national focus on 
addressing racial inequities in care has exposed huge disparities in how different populations 
fare with respect to substance use disorders (SUDs), but also generated new support for 
addressing those disparities. The 2020 roadmap is organized around the same six essential 
policy goals as the 2019 version, but goes into far greater detail, provides extensive tangible 
action items, and details best practices in more than two dozen states.
Exhibit 1. Progress update on AMA–Manatt Health 2019 policy recommendations
  Evidence-based treatment for opioid use disorder. Provide the full continuum of 
care, including medications to help treat opioid use disorder (MOUD) that are provided 
equitably across the health care system.
 – Results are mixed. The COVID-19 pandemic has brought new challenges 
and increased mortality from illicit fentanyl, methamphetamine and cocaine. 
More states have enacted laws prohibiting health insurers from using prior 
authorization for MOUD, but more than half of the nation’s states still allow it.
  Parity enforcement. Increase oversight and enforcement of mental health and 
substance use disorder parity laws, including prospective evaluation of payer 
compliance.
 – Results are mixed. Some states have enacted meaningful laws, and 30 states 
have joined a new National Association of Insurance Commissioners (NAIC) work 
group to refine regulatory tools that can hold insurers accountable. Yet state and 
federal oversight remains limited, as exemplified by the regular parity violations 
that are found when states conduct compliance exams.
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  Network adequacy/workforce enhancement. Ensure adequate networks that 
allow for timely access to addiction medicine, psychiatry and other physicians trained 
to treat addiction and mental illness; support payment reforms, collaborative care 
models, and other efforts to bolster and support the nation’s substance use disorder 
treatment workforce.
 – Much more work remains. Innovative payment models continue to be explored, 
and some states are working hard to increase access to care, but millions of 
Americans with an SUD and/or mental illness remain without treatment.
  Pain management. Enhance access to comprehensive, multidisciplinary, multimodal 
pain care, including nonopioid and nonpharmacologic pain care options; remove 
arbitrary restrictions on opioid therapy for patients with pain.
 – Much more work remains. While policymakers continue to rely on arbitrary 
restrictions for opioid analgesics, states and insurers have done relatively little to 
increase access to evidence-based alternatives to opioids and other medications 
and treatments that have proved cost effective in treating pain.
  Harm reduction. Reduce harm by expanding access to naloxone, supporting sterile 
needle and syringe exchange programs, and coordinating care for patients in crisis.
 – Progress continues. If not for naloxone, it is likely that tens of thousands more 
Americans would have died in 2019-2020. Some states have taken steps to 
increase access to sterile needles and syringes, and emergency departments are 
showing great promise in helping coordinate care for patients who experience an 
overdose event.
  Data surveillance and evaluation. Support standardized data collection and 
surveillance efforts, and evaluate policies and outcomes to identify effective policies 
and clinical interventions so as to build on the most successful efforts, and also to 
identify policies and programs that may need to be revised or rescinded.
 – Much more work remains. States are taking action to gather more information, 
but they need to take the next step to turn that data into effective overdose 
prevention, treatment, and targeted interventions. Few states have evaluated 
whether current policies are increasing access to care or reducing opioid- and 
drug-related harms. There remains a lack of standardized data collection efforts 
across states, and data collection to address racial, ethnic, and gender-related 
inequities also is limited at best.
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The goal of our 2020 roadmap is to highlight 
the areas where there is opportunity 
for improvement, as well as to build on 
the progress that has been made by 
providing tangible recommendations 
and best practices to increase access to 
evidence-based care for SUDs, support 
multidisciplinary, multimodal treatment 
for patients with pain, and expand the use 
of proven and promising harm reduction 
strategies. With respect to COVID-19, which 
has contributed to the again-rising overdose 
death rate (see Exhibit 2), the roadmap 
highlights the accelerated use of telehealth and other policy changes that could become part 
of short- and long-term strategies to improve access to overdose prevention and treatment 
strategies. Removing the stigma for those who receive treatment for an SUD, for patients with 
pain, and for people who use drugs remains a long-overdue need across all domains.
Exhibit 2. 12 month-ending provisional counts of drug overdose deaths by drug or drug 
class, United States, 2015–2020
Data last updated November 4, 2020.
Source: www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm.
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Exhibit 3. The opioid epidemic continues to evolve into a broader polysubstance use 
and more deadly drug overdose epidemic
The opioid epidemic continues to evolve into a more deadly and broader drug overdose 
epidemic, with more people dying from illicit fentanyl, heroin, cocaine, and stimulants 
even as the country experiences a dramatic drop in the use of prescription opioids. 
According to the US Centers for Disease Control and Prevention (CDC), from the 
beginning of 2015 to the end of 2019:2
  Deaths involving illicitly manufactured fentanyl and fentanyl analogs increased 
from 5,766 to 36,705.
  Deaths involving stimulants (eg, methamphetamine) increased from 4,402 to 16,353.
  Deaths involving cocaine increased from 5,496 to 16,055.
  Deaths involving heroin increased from 10,788 to 14,151.
  At the same time, deaths involving prescription opioids decreased from 12,269 to 
11,973. (Deaths involving prescription opioids reached their highest point in July 2017, 
at 15,003.)
The 2020 roadmap also highlights the need 
to more directly address long-standing 
inequities in access to SUD treatment for 
Black and Hispanic Americans and other 
racial and ethnic groups, including an 
emphasis on ensuring that policy and 
clinical interventions directly confront those 
inequities. This analysis must acknowledge 
that the opioid epidemic continues to 
evolve into a more deadly and complicated 
polypharmacy and illicit drug overdose 
epidemic, creating an even greater need 
to treat it as part of a larger substance use 
disorder epidemic and for policymakers to 
continually evaluate the effectiveness of 
their policies and pivot when needed.
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Exhibit 4. Sharp racial inequities persist in access to SUD treatment and pain care
Despite experiencing rates of SUD similar to those of White Americans, Black Americans 
and other historically minoritized and marginalized groups experience sharp disparities in 
access to SUD treatment due to a range of factors, including:
  Double stigma among Black Americans who have an SUD due to stereotypes that have 
mislabeled them as more likely to use illicit substances and to feel less pain
  Fear of legal consequences and significant mistrust of the health care, social services, 
and justice systems given Blacks’ long history of disproportionately lengthy sentencing 
and incarceration
  Shortage of providers who are Black or are from other minoritized communities and, in 
particular, shortages in opioid treatment programs (OTPs), as well as in physicians and 
other health care professionals serving Black, Hispanic and other communities.3
Taken together, these and other factors contribute to harsh disparities in access to treatment. 
One study found that for every appointment where a Black American received a prescription 
for buprenorphine, White patients had 35 such appointments.4 These inequities translate 
directly into differing mortality rates across racial and ethnic groups. In 2018, when the nation 
was beginning to see a decline in overdose deaths, it was due entirely to gains among White 
Americans. The rate of drug-induced deaths for American Indians, Asians, Black Americans, and 
Latinos actually increased and appears to have continued to increase in 2019 at a rate higher 
than among White Americans.
A. Address the implications of COVID-19 for the drug overdose epidemic
COVID-19 has exacerbated the nation’s drug overdose 
epidemic, impacting people with substance use 
disorders and the physicians and other health care 
professionals who serve them.5 National, state, and 
local media reports indicate that these strains are 
sharply pushing up overdose rates.6 Although not 
enough to overcome rising overdose rates, providers 
and government agencies moved quickly to enable 
new flexibilities to provide care options for patients 
with an SUD and for patients with pain.
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Drivers of increases in overdose. The COVID-19 pandemic has created a challenging 
environment for many, including patients with pain and patients with an SUD/OUD due to:
  More financial instability, stress, and anxiety. The stress of contracting COVID-19 or 
facing the loss of family members and friends, coupled with job loss and job insecurity, has 
contributed to high levels of stress and anxiety. Between March and June 2020, the CDC 
found that stress and anxiety were up across the board, with adults and, in particular, young 
adults reporting alarmingly high rates of thoughts about suicide.7
  Social isolation. The COVID-19 pandemic has increased social isolation, a particular 
challenge for people with an SUD who rely on social connections as part of their treatment 
and recovery. While some peer recovery services and groups moved online, these online 
forums do not always work as well for many people with an SUD. COVID-19 has also caused 
individuals to use drugs alone, which increases the chance of fatal overdoses because there 
is no one who can help respond to the overdose.8
  Disruptions in access to treatment options and harm reduction services. Physicians 
and other health care professionals who provide addiction medicine and behavioral health 
care are being further squeezed as states face budget shortfalls, prompting shutdowns 
or reductions in service options. Potential patients may also face more limited in-person 
options, requirements to pass COVID-19 tests prior to securing treatment, and changes 
in where and when they can secure help. While the shift to telehealth has opened up 
important options in MOUD access, lack of technology access among some people with SUD 
has disrupted treatment. Harm reduction services that provide primary overdose prevention 
or sterile needle and syringe services may have become more limited, altered hours, or more 
difficult to reach during COVID-19.
Elyse Powell, PhD State Opioid Coordinator, North Carolina Department of Health and Human 
Services, summarized the implications of COVID as follows: “This pandemic has exacerbated 
many gaps and inequities that were already present in our systems to support people 
with substance use disorders. The national spike in overdoses seen during COVID is further 
evidence that harm reduction services, treatment services, and behavioral health services are 
essential services.”
Policy innovations. In response to the COVID-19 pandemic, certain flexibilities were enabled 
to ensure providers and patients with an OUD or pain had continued access to necessary care 
and treatment options. These include:
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  Expanded use of telehealth. In March 2020, the federal government offered increased 
flexibility to allow for the initiation of buprenorphine via telehealth, including through 
telephone-only services, which has proved particularly critical for many people with an SUD 
and/or pain.9 For example, emergency rules in Texas were extended to help ensure patients 
with chronic pain have continued access to necessary pain care. The extension allows 
for “telephone refill(s) of a valid prescription for treatment of chronic pain by a physician 
with an established chronic pain patient.”10 An AMA survey of pain medicine physicians 
found that 80 percent of physician respondents said that the flexibilities provided by the 
DEA during the COVID-19 pandemic have been either very helpful or somewhat helpful 
for treating patients with pain.11 The AMA strongly supports these flexibilities, including 
the authority “to allow DEA-registered practitioners to begin issuing prescriptions for 
controlled substances to patients for whom they have not conducted an in-person medical 
evaluation.”12
  Easing access to medications. The federal government gave states the flexibility to 
allow opioid treatment programs (OTPs) to support take-home doses of methadone for 
up to 28 days at a provider’s clinical discretion. States also offered extended supplies 
of medications and, in some instances, eliminated prior authorization requirements, as 
recommended by last year’s AMA-Manatt roadmap, for MOUD.13 For example, in Minnesota, 
a new law was passed in April 2020 in response to COVID-19 that protects patients with 
chronic pain, OUD, and other medical diseases by increasing access to critical medications 
through relaxed refill limits on controlled substances. The law permits Schedule II-V 
substances to be dispensed for more than 30 days, and it removed existing refill limitations 
to encourage patients who rely on these medications to continue appropriate treatments 
while staying safe.14
  Easing counseling requirements. Even prior to COVID-19, organizations such as the 
National Academy of Sciences and the American Society for Addiction Medicine (ASAM) 
were recommending that government agencies and providers allow people to receive 
MOUD even if they cannot or do not opt to participate in recommended counseling and 
therapy. In response to COVID-19, states such as West Virginia temporarily suspended 
counseling requirements for the duration of the public health emergency, making it easier 
for people to secure MOUD.15
Going forward, it will be important to evaluate and retain those changes in telehealth, 
counseling, and access to MOUD that have helped sustain individuals with chronic pain and/or 
an SUD engaging in treatment during the pandemic.
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B. Fix the broader structural and systemic barriers to treatment
Beyond the specific challenges raised by COVID-19, access to evidence-based care remains 
a barrier to many seeking treatment for an SUD due to ongoing structural and systemic 
challenges. We once again emphasize:
  States must be willing to use their oversight and enforcement authority. State 
regulators have differing degrees of authority to pursue policies and changes that can have 
a significant impact on reducing barriers and improving patient care, but the extent to 
which they use these tools to increase access to evidence-based treatment or hold payers 
and others accountable for delayed and denied access varies considerably.
  Medicaid often leads the way. Medicaid is a major payer for SUD treatment, serving four 
in ten individuals with an OUD in the United States. It often provides more comprehensive 
SUD care than the commercial insurance market and, in all states, has been a driving force 
for greater use of MOUD.16 During the COVID-19 pandemic, many states have used their 
Medicaid flexibility to provide additional funding to SUD providers facing declining revenue 
and new COVID-19–related costs, as well as to dramatically expand use of telehealth for SUD 
treatment.17
  Grants are helpful, but long-term implementation needs long-term, sustainable 
funding. Many best practices that are helping save lives are currently grant funded and 
need long-term, sustainable funding to continue benefiting individuals with an SUD. 
Without reliable funding streams, programs that help save lives may simply stop. This 
issue has become even more important with the large influx of federal dollars during the 
COVID-19 pandemic and the potential that termination of these emergency funds will 
leave gaping holes that will be exceptionally hard to fill for states facing significant budget 
pressures.
Exhibit 5. Effectiveness of federal funding should be evaluated
According to the Bipartisan Policy Center, $15 billion was spent in 2019–2020 to help end the 
epidemic, three-quarters of which went to treatment, recovery, and prevention. We agree 
with the center’s recommendation that, “[g]iven the size of this investment, publicly available 
evidence-based evaluations of each of the streams of federal opioid funding must be conducted. 
These evaluations should include information on whether the grant is meeting the needs of 
at-risk populations as well as health equity goals. In addition, evaluations should assess whether 
federal resources are going to implement evidence-based interventions.”
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  Evaluation must include both 
policy outcomes and surveillance 
data to address prevention. Few 
states have undertaken efforts to 
evaluate current laws, policies, and 
programs to determine whether 
those policies, programs, and laws 
are working to increase access to 
evidence-based care and reduce 
harm. If they have not had their 
intended outcomes, it is imperative 
to critically examine why and address 
policy shortcomings. Similarly, 
state-level surveillance efforts 
must develop and grow in multiple ways. Not only must data collection and surveillance 
efforts include nonfatal overdose as well as mortality to ensure resources are used to 
support overdose prevention and treatment, but increased emphasis must be placed on 
data collection and surveillance that is disaggregated to highlight differences by race, 
ethnicity, age, gender, and other factors critical to confronting health inequities. In designing 
evaluation studies, it will be critical to go beyond narrow cost-benefit analyses to measure 
outcomes in broad social terms.
Exhibit 6. State officials recognize the need to increase access to evidence-based 
treatment
“Access to mental health, behavioral health and substance use disorder treatment is even 
more important now due to the current COVID-19 public health emergency. Rates of anxiety, 
depression, and grief related to social isolation have increased, and these conditions are further 
exacerbated for certain communities of color and communities that face structural barriers to 
accessing care. These issues are not new, but current events do heighten the urgency to ensure 
compliance with state and federal parity laws.”18
—Michael Conway, Colorado commissioner of insurance
“Maine’s comprehensive Opioid Response Strategic Action Plan focuses on Prevention, 
Treatment, Harm-Reduction and Recovery Support. We need to be successful in all of these 
critical areas if we hope to successfully respond to this epidemic. Our work is now challenged by 
the global pandemic. Both the epidemic and the pandemic pose dangerous risks to public health 
and both deserve the immediate attention of every citizen.”
—Gordon H. Smith, Esq., Maine director of opioid response
“The COVID-19 pandemic has created 
new challenges and exposed existing 
cracks in our nation’s treatment system. 
The nation’s overdose epidemic grows 
worse. Policymakers must decide that 
the status quo is unacceptable and 
remove all barriers to evidence-based 
care. Unless and until this occurs, more 
Americans will die.”
Patrice A. Harris, MD, MA, Immediate Past 
President, American Medical Association; Chair, 
AMA Opioid Task Force
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II. Increase access to evidence-based treatments 
to help patients with a substance use disorder
As with any condition, it is critical that people with a substance use disorder have access to 
medically appropriate care, taking into account their individual needs and circumstances. 
More than eight in ten people with a substance use disorder (82.6%) who need treatment 
do not receive it.19 Moreover, among those with an opioid use disorder, many still do not 
receive MOUD even though evidence is clear that MOUD helps save lives and has numerous 
benefits; the US surgeon general continues to emphasize that MOUD is the “gold standard” 
of treatment for OUD.20 Patients who use MOUD remain in therapy longer and are less likely 
to use illicit opioids. The result is that SUD treatment helps decrease overdose deaths, reduces 
the transmission of infectious diseases, including HIV and hepatitis C,21 and leads to reduced 
recidivism and other benefits to society, including lower rates of crime.22,23
Despite the evidence base for MOUD, barriers to it persist, including inconsistent coverage of 
all US Food and Drug Administration (FDA)-approved forms of MOUD,24 inadequate provider 
networks, stigma that keeps some individuals and providers from using MOUD, lack of 
provider education and comfort with providing MOUD, high cost sharing for MOUD, and prior 
authorization requirements. These barriers can make the difference between a person being 
willing to pursue treatment or continuing to misuse opioids and risking death by overdose.
State responses have been mixed: 21 states and the District of Columbia have enacted laws 
that limit public and/or private insurers from imposing prior authorization requirements on an 
SUD service or medication, but the remaining states have not yet done so.25 The AMA helped 
support passage of more than a dozen of those laws in 2019 and 2020. Unfortunately, health 
insurers are often opponents of these laws, despite the fact that many health plans have 
trumpeted their voluntary pledges to reduce administrative barriers to MOUD.26 There is no 
evidence that premiums have increased in states that have removed prior authorization for 
MOUD, an observation that may be of importance to policymakers navigating this debate.
Beyond MOUD, individuals with an SUD require access to the full SUD treatment and 
withdrawal management continuum of care. Investing in SUD treatment has demonstrated 
economic and societal benefits. For example, studies have found that every dollar spent on 
SUD treatment saves $4 in health care costs and $7 in law enforcement and other criminal 
justice costs.27 As established by the ASAM, this includes early, preventive interventions, 
outpatient services, residential services, and medically managed inpatient services.28 The 
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appropriate level of care depends on the nature of the person’s substance use disorder, as well 
as their physical health, emotional health, willingness to enter treatment, living and family 
circumstances, and earlier treatment experiences. Individuals with an SUD often are directed 
to the level of care provided by the organization conducting their intake, rather than the level 
of care that is most appropriate for them based on a thorough assessment and an informed 
decision made in consultation with their physician or other health care professional.
Exhibit 7. Facing addiction in America
“We all ask the same question: How can I contribute to ending the opioid crisis and 
helping those suffering with addiction? The first step is understanding that opioid use 
disorder is a chronic but treatable brain disease, and not a moral failing or character flaw. 
Like many other chronic medical conditions, opioid use disorder is both treatable and, in 
many cases, preventable. It is also a disease that must be addressed with compassion.”29
—Jerome M Adams, MD, MPH, surgeon general
A. Eliminate all barriers to MOUD in Medicaid
Following persistent public education and advocacy campaigns, Medicaid programs are 
now more likely to cover MOUD, but significant barriers remain. These include some gaps 
in coverage but, more often, utilization management strategies that delay or deter access—
preferred status, prior authorization requirements, quantity limits, step-therapy requirements, 
and counseling requirements. In addition, stigma around MOUD remains, posing challenges 
for patient access. There must also be additional efforts to prohibit polices that someone 
must have failed withdrawal attempts, or failed at abstinence-based treatment, as a condition 
of MOUD.
A recent review by the Medicaid and CHIP Payment and Access Commission (MACPAC) found 
that the majority of state Medicaid programs (30 in 2018) still require prior authorization for at 
least one MOUD medication. Although the SUPPORT (Substance Use-Disorder Prevention that 
Promotes Opioid Recovery and Treatment) Act requires Medicaid to cover all forms of MOUD 
as of October 1, 2020, it remains possible that some states will cover some formulations but 
not others. For example, they might cover an oral formulation of buprenorphine but not an 
injectable or implantable formulation, despite the recommendations of the patient’s physician 
that one formulation is preferred. For example, if patient adherence is an issue, a long-acting 
formulation might be more beneficial than a formulation requiring daily administration.
2020 National Roadmap | 12
Of particular note, many Medicaid beneficiaries face steep barriers when it comes to securing 
methadone despite four decades of evidence demonstrating it is an effective method to 
reduce cravings, use of opioids, and mortality.30 As of 2019, multiple states did not cover 
methadone under Medicaid for purposes of 
MOUD, including Idaho, Kansas, Kentucky, 
Louisiana, Nebraska, Tennessee, and Wyoming.31 
However, even when methadone is covered, 
other barriers remain; methadone can only 
be provided by specially licensed OTPs that 
are tightly and jointly regulated by the Drug 
Enforcement Agency and SAMHSA and also are 
subject to varying state requirements, including restrictive zoning, leading to wide variation 
in the availability of OTPs across states. For example, Wyoming began covering methadone 
through Medicaid as of October 1, 2020,32 but there are no methadone clinics operating in 
the state, which means that the medication likely remains unavailable despite the stated 
coverage policy.33
Stigma remains a key challenge to expanding access to MOUD. Stigma hampers recognition 
that SUD is a medical illness and should be treated with appropriate medication like other 
medical conditions. Because buprenorphine and methadone are opioids, the erroneous belief 
that individuals who receive MOUD are substituting one drug for another is widespread.34 This 
thinking amplifies abstinence-only approaches as the only method to achieve recovery, and 
can lead many residential and recovery housing programs to refuse care for individuals who 
receive MOUD.
In 2019 and the first part of 2020, some states took steps to expand their coverage of MOUD 
and eliminate unnecessary prior authorization and utilization management strategies. For 
example, according to Kaiser Family Foundation, three states added coverage of Vivitrol, 
a long-acting injectable form of naltrexone, in fiscal year 2019 and fiscal year 2020, while 
21 states reported changes in their prior authorization requirements to improve access 
to MOUD.35
In sum, it is critical to cover all forms and formulations 
of MOUD, including methadone, but also to go beyond 
coverage to eliminate prior authorization and other 
utilization management strategies that deter the use of 
medications. There simply is no medical or policy need 
that justifies delaying or denying access to MOUD—
particularly during an epidemic.
As of 2019, multiple states did 
not cover methadone under 
Medicaid for purposes of 
MOUD, including Idaho, Kansas, 
Kentucky, Louisiana, Nebraska, 
Tennessee, and Wyoming.
There simply is no medical 
or policy need that justifies 
delaying or denying access 
to MOUD—particularly 
during an epidemic.
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RECOMMENDATION: State Medicaid officials should continue to expand 
Medicaid coverage of MOUD of all types and all formulations, eliminate 
prior authorization and utilization management barriers, and revisit state 
requirements that deny the availability of methadone and OTP access for 
patients seeking care.
B. Reduce MOUD barriers in commercial insurance
State insurance regulators often lack the authority to order commercial insurers to cover 
MOUD, which has led to a variety of strategies, from insurance regulators and attorneys general 
negotiating agreements with insurers to legislation in 17 states prohibiting state-regulated 
commercial insurers from imposing prior authorization requirements on SUD medication. Most 
of these laws have been enacted in the past two years, and they vary in comprehensiveness. 
While most of these laws remove prior authorization for “at least one modality” of MOUD 
without specifying additional requirements, only a few cover a more comprehensive set of 
MOUD or include language that encompasses all FDA-approved SUD medications with enough 
specificity to ensure comprehensive coverage. For example:36
  In New York, regulations are comprehensive and robust, stating that a plan may not impose 
prior authorization for an initial or renewal prescription for all buprenorphine products, 
methadone, or long-acting injectable naltrexone for either detoxification or maintenance 
treatment of an SUD.
  Missouri regulations are also relatively comprehensive, specifying that commercial 
health plans must cover buprenorphine tablets, methadone, extended-release injectable 
naltrexone, and buprenorphine/naloxone combination (and those dispensed through an 
opioid treatment program) without prior authorization.
  In Arkansas, regulations are less comprehensive, stating that insurers cannot impose prior 
authorization requirements for buprenorphine, naltrexone, and methadone without 
specifying whether they apply to all modalities of each MOUD type.
While these laws represent progress, it remains important for insurance regulators to monitor 
and ensure compliance. In some states, such as Pennsylvania, the Insurance Department was 
able to secure voluntary agreements among leading carriers to eliminate prior authorization 
for MOUD and take additional steps, such as requiring that MOUD cost sharing be minimal. 
As with many laws, there are important provisions, such as which medications are covered 
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and what cost sharing is allowed, that require regulatory attention. For the laws to function 
as intended, insurance regulators will need to work with payers, the medical community, and 
patient advocates to ensure that MOUD is routinely available in daily practice.
RECOMMENDATION: States should require commercial insurers to eliminate 
prior authorization requirements and other burdensome utilization 
management practices for MOUD. MOUD should be placed on the lowest 
cost-sharing tier of health insurer/pharmacy benefit manager (PBM) 
formularies to help increase access to affordable MOUD options. In states 
that have taken these steps, state insurance regulators and attorneys 
general should conduct meaningful review to ensure that health insurers 
and PBMs are complying with the law and fulfilling plan benefits.
C. Promote access to the full continuum of care
While MOUD is critical for many with an opioid use disorder, a much broader range of services 
is needed to meet patient needs, including evidence-based mental and behavioral health 
care. To ensure that people can secure the most effective treatment for their individual 
circumstances, it is important for Medicaid and commercial insurers to cover the full continuum 
of care recommended by the ASAM, the American Academy of Addiction Psychiatry (AAAP), 
and other professional medical associations. In addition, people with an SUD should undergo 
an evidence-based assessment with their physician or other health care professional to identify 
the appropriate level of care.
Increasingly, state Medicaid programs are requiring use of an evidence-based assessment 
and access to the full continuum of care, in some cases because they are required to do so 
as part of their 1115 SUD waiver. The complete continuum of care for SUD services includes 
early intervention services, outpatient and intermediate outpatient services, residential and 
other inpatient services, and withdrawal management services. A complete continuum of care 
ensures that individuals with specialized needs, including those with co-occurring mental 
health disorders, cognitive impairments (eg, traumatic brain injury), and developmental 
disabilities, have access to tailored programs that are appropriate for their circumstances. 
Additionally, what constitutes the complete continuum of care differs for adolescents, adults, 
and older adults, whose needs vary.
State Medicaid programs like those in North Carolina, Pennsylvania, Virginia, and West Virginia 
are working toward expanding their SUD treatment services to encompass the complete ASAM 
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continuum of SUD treatment. These states require providers to use the ASAM criteria to assess 
and place Medicaid enrollees in the appropriate level of care.
Similar requirements do not generally exist for commercial insurers, though California is a 
notable exception. California recently adopted legislation that requires insurers as part of 
the Mental Health Parity Act to provide parity of coverage for all mental health and SUD 
conditions within the most recent edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM), including at “intermediate levels of care,” which includes (but is not limited 
to) residential treatment, partial hospitalization, and intensive outpatient services. The law also 
bans limitations on coverage for mental health and SUD to “short-term or acute treatment.”37
RECOMMENDATION: States should require all public and commercial payers 
to cover the full continuum of care as recommended by professional medical 
associations for SUD treatment and withdrawal management. This should 
include services that meet the needs of a diverse patient population as 
appropriate for their individual patient needs and circumstances.
D. Address inequities in treatment options
The opioid epidemic—and the larger drug overdose epidemic—has affected all racial groups. 
It is essential that we have the data to ensure that public health interventions are specifically 
tailored to ensure affordable, equitable access for historically minoritized and marginalized 
populations. The AMA is very concerned by increasing numbers overall, and consistent 
with efforts to ensure access and promote health equity, highlights the recent increasing 
percentages of opioid-related mortality among Black, Latinx, American Indian, Native Alaskan, 
and other minoritized populations. While people who self-identify as White remain far 
more likely to die of a drug overdose than people who identify themselves as Black, African 
American, Hispanic, American Indian, Native Alaskan, and other minoritized populations this 
emerging trend must be addressed.
Racial and ethnic differences in access to evidence-based treatment need to be considered 
and confronted. We must remove any and all systemic barriers to treatment by race, gender, or 
ethnicity. We must further not associate rates of use without discussing and recognizing how 
those systemic barriers may be exacerbated by social/structural/political determinants and 
other factors. Researching, understanding and confronting upstream causes and downstream 
effects of these factors are complicated, but essential components to breaking down systemic 
health inequities. Data can reveal certain trends in use and mortality by race, gender and 
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ethnicity, but one of the keys is to use that data to implement equitable solutions to increase 
access to prevention and treatment, which will necessarily need to address primary, secondary 
and tertiary levels of prevention.
According to the CDC, while prescription opioid-involved death rates decreased by 13.5% from 
2017 to 2018, these gains are attributable largely to decreases in overdose deaths by non-
Hispanic Whites (see Exhibit 8).38 Even though non-Hispanic Blacks and Hispanics (as defined 
by CDC) remain far less likely than Whites to die of opioid overdoses, these latest data warrant 
close attention (Whites had an opioid-related overdose death rate of 19.4 per 100,000 in 2017, 
compared to 15.7 for American Indian/Alaska Natives, 12.9 for Blacks, and 6.8 for Hispanics in 
the same year).39 In the same time frame, death rates involving synthetic opioids (eg, illicitly 
manufactured fentanyl and fentanyl analogs) increased from 9.0 per 100,000 population 
in 2017 to 9.9 in 2018 and accounted for 67% of opioid-involved deaths in 2018. The recent 
increase in death rates involving synthetic opioids is driven in part by an increase in mortality 
among minority groups; according to the US Agency for Healthcare Research and Quality,40 
from 2013 to 2017, non-Hispanic Blacks had an 18-fold increase in mortality due to synthetic 
opioids other than methadone, Hispanics had a 12.3-fold increase, and non-Hispanic Whites 
had a 9.2-fold increase.
Exhibit 8. Opioid overdose deaths by race/ethnicity, 1999–2018, Kaiser Family Foundation
Source: www.kff.org/other/state-indicator/opioid-overdose-deaths-by-raceethnicity/?activeTab=graph&currentTimeframe=
0&startTimeframe=19&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D.
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SAMHSA’s 2020 report, “The Opioid Crisis and the Hispanic/Latino Population: An Urgent 
Issue,”41,42 represents an important direction in working to provide, specific to the Hispanic/
Latino population in the United States: (1) “recent data on the prevalence of opioid misuse 
and opioid overdose death rates”; (2) “contextual factors that impact the opioid epidemic 
in these communities”; (3) “innovative outreach and engagement strategies that have the 
potential to connect individuals with evidence-based prevention, treatment, and recovery”; 
and (4) “the importance of ongoing community voice and leadership in the development and 
implementation of solutions.”
Data that reveal differences and disparities in equitable prevention and treatment initiatives 
and outcomes are critical for targeting policy interventions to ensure the greatest impact for 
prevention and treatment. For example, according to a recent study of all US counties,43 where 
Black/African American and Hispanic Americans live plays a strong role in the type of medication 
that they may be offered, creating inequities in medication access and treatment availability in key 
communities that have been disproportionately impacted by the epidemic. SAMHSA describes 
the United States system as “a two-tiered treatment system … where buprenorphine is accessed 
by Whites, high-income, and privately insured, methadone is accessed by people of color, low-
income, and publicly insured.”44 Given the critical importance of providing people with treatment 
options consistent with their individual circumstances, it is deeply problematic that some forms of 
MOUD are not equally available to many minoritized and marginalized populations.
To address equity issues, states and commercial insurers have a number of options, including:
  Supporting physicians and other health care professionals who serve a relatively high 
number of Black, Latinx, American Indian and Native Alaskan people, in securing their Drug 
Addiction Treatment Act (DATA) waiver (accompanied by appropriate reimbursement)
  Providing training on offering culturally appropriate care
  Gathering, monitoring, and acting on treatment data disaggregated by race, ethnicity, 
gender, and age in a timely manner
  Involving communities in developing and implementing policy change
For example, as highlighted by SAMHSA in its recent report, “The Opioid Crisis and the Black/
African-American Population: An Urgent Issue,” organizations such as the Detroit Recovery 
Project work in partnership with local hospitals, clinics, and other health care providers to offer 
a wide array of recovery services tailored to Black/African Americans. The Detroit Recovery 
Project has developed memorandums of understanding with local federally qualified health 
centers to offer recovery coaches and facilitates regular town hall meetings to address the 
impact of the opioid epidemic on Detroit’s Black/African American communities.45
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Exhibit 9. Opioid overdose deaths by 
race/ethnicity, percentage Hispanic, 2018, 
Kaiser Family Foundation
Exhibit 10. Opioid overdose deaths by 
race/ethnicity, percentage Black, Non-











The maps indicate that there also are significant regional differences in how the drug overdose 
epidemic impacts minority populations. Data on opioid overdose deaths show that states with 
larger Hispanic/Latino populations observe higher rates of opioid overdose among Hispanic/
Latino adults, including California, Texas, New Mexico, and states with larger Black populations 
observe a similar trend for opioid overdose deaths among Black adults, including as Illinois, 
Missouri, and Michigan (see Exhibits 9 and 10). However, it’s important to note that these 
data are not inclusive of the COVID-19 pandemic time frame. This is one reason the AMA has 
urged national and state public health officials to increase efforts to provide more timely and 
actionable data—data that are disaggregated by race, ethnicity, gender, and age. To have the 
greatest positive impact on reducing overdose mortality, it’s essential to have more timely data 
to guide public health interventions.
RECOMMENDATION: States should ensure that public and commercial 
payers collect, analyze, and make public provider and treatment utilization 
data disaggregated by race and ethnicity, ensure that racial and ethnic 
disparities are meaningfully addressed in providing equitable access to 
and utilization of SUD treatment and support, and take an active role in 
engaging the community and advocating for policy changes that advance 
equity and access to culturally appropriate care.
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E. Eliminate treatment barriers for pregnant, parenting, and postpartum 
women and justice-involved populations
Some particularly vulnerable groups face distinct barriers to coverage. These include 
individuals incarcerated in jail or prison, many of whom may be incarcerated in part due 
to their SUD or a related mental health issue. Since the landmark case of Estelle v Gamble in 
1976, the Supreme Court has held that all incarcerated individuals have the right to adequate 
medical care, and officials who show a “deliberate indifference” to someone’s serious medical 
needs are in violation of the cruel and unusual punishment clause of the Eighth Amendment. 
Even so, it remains common for jail and prison officials to deny SUD treatment, including 
MOUD, to justice-involved individuals. Increasingly, this practice is being legally challenged 
and courts are clarifying that a failure to provide SUD treatment represents a violation of the 
Americans with Disabilities Act and the Eighth Amendment.
Exhibit 11. Courts increasingly are ruling that MOUD must be provided 
to incarcerated individuals
In a few recent lawsuits, courts have ruled that failure to provide physician-prescribed 
medications for opioid use disorder to people in jail or prison violates the Eighth 
Amendment’s ban on cruel and unusual punishment and the Americans with Disabilities Act, 
which prohibits discrimination on the basis of disability, including against people in recovery 
for OUD.
  Pesce v Coppinger.46 Mr Pesce was a middle-aged man who had been in active recovery 
for two years on methadone. In 2018, he was sent to jail for 60 days for driving without 
a license while on his way to pick up his methadone dose, but the jail to which he was 
assigned would not agree to continue his methadone treatment. After he sued, the court 
ruled that the jail must continue his methadone treatment, citing in part his doctor’s 
opinion that involuntary withdrawal of treatment would cause Mr Pesce “severe and 
needless suffering [that would] jeopardize his long-term recovery and is inconsistent with 
sound medical practice.”
  Smith v Aroostook County.47 Brenda Smith was in recovery for a period of about ten 
years when she was sentenced to 40 days in jail for theft. She ultimately secured the right 
to continue suboxone while serving her sentence on the grounds that denial of MOUD 
(buprenorphine, in this case) would cause serious and irreparable harm and violate the 
Americans with Disabilities Act. While jails and prisons sometimes maintain they cannot 
safely dispense MOUD due to diversion risk, Ms Smith’s lawyers pointed out that the jail 
was able to treat pregnant women. In a significant win for patients with OUD, the US Court 
of Appeals for the First Circuit upheld the district court’s ruling for Ms Smith.
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One example of a promising state-led initiative is in North Carolina, which has implemented 
several new programs to expand MOUD to justice involved individuals. The state Department 
of Health and Human Services (NCDHHS) is committing over $16 million to fund jail-based 
medication assisted treatment programs that induct or continue treatment while people are 
incarcerated, community-based pre- and post-arrest programs to divert people with substance 
use disorders from jail to appropriate treatment options as well as create re-entry programs 
that help connect people to care upon release from incarceration. In a partnership between 
NCDHHS and the Department of Public Safety, North Carolina is also piloting MOUD induction 
in three prison re-entry facilities so that people exiting incarceration are connected to MOUD 
as part of their re-entry process. According to state data, “formerly incarcerated individuals are 
40 times more likely than other North Carolinians to die of an overdose in the first two weeks 
of re-entering the community.”48
Pregnant women also often face barriers to treatment, which is particularly problematic given 
that lack of treatment increases the risk of poor birth outcomes along with risk to the mother’s 
health. Using a “secret shopper” approach across ten states, the authors of a recent study 
found that “callers representing pregnant women were less likely than callers representing 
nonpregnant women to be granted an appointment with an opioid use disorder treatment 
clinician.” More than 28,000 calls were made during the study period. The authors compared 
access to buprenorphine-waivered clinicians and opioid treatment programs for women with 
private insurance or Medicaid.
Among the findings:49
  “With both buprenorphine-waivered prescribers and OTPs, insurance was associated with 
appointment access.”
  “Nonpregnant callers with Medicaid were less likely than nonpregnant callers with private 
insurance to be granted an appointment with buprenorphine-waivered prescribers.”
  For 26% of buprenorphine-waivered prescribers and 32% of OTPs, appointments were 
offered only when the caller said she could pay cash.
There also are systemic, stigmatizing barriers faced by pregnant women, including that if 
they seek care during MOUD treatment or while using drugs, they may be subject to criminal 
penalties—creating a deterrent to care that could harm the woman and fetus. For example, 
23 states and the District of Columbia still consider substance use during pregnancy to be child 
abuse under civil child-welfare statutes, and three consider it grounds for civil commitment. 
Moreover, 25 states and the District of Columbia require health care professionals to report 
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suspected prenatal drug use, and eight states require them to test for prenatal drug exposure if 
they suspect drug use.50
Of particular note, as described in Exhibit 12, incarcerated pregnant women with an SUD often 
do not receive appropriate medical care or receive it only until they deliver, at which point they 
are taken off physician-prescribed medications.
Exhibit 12. Treatment for incarcerated pregnant women is limited and often 
stopped after delivery
New research from Johns Hopkins University highlights that a substantial share of 
pregnant women who are incarcerated have an opioid use disorder—26% of women 
admitted to prisons and 14% of women admitted to jails. Most jails and prisons will not 
initiate MOUD for a pregnant woman who is incarcerated, although they are more likely 
to maintain it for the duration of the pregnancy if she enters on MOUD. Among those 
institutions that do provide MOUD, two-thirds of prisons and three-quarters of jails 
discontinue it after delivery. As the authors conclude, “[p]regnant incarcerated women 
with opioid use disorder in the United States frequently appear to be denied essential 
medications and receive substandard medical care.”51
In response to these barriers, several states have begun conducting active outreach to 
obstetrician-gynecologists (OB-GYNs) to educate them about the importance of identifying 
and treating SUD in women and support them in securing DATA waivers. Other states are 
revisiting laws that criminalize women with an SUD who are seeking treatment. For example:
  Health care professionals in West Virginia who provide treatment for SUDs and accept 
Medicaid must give pregnant women priority in accessing services.52
  Wisconsin provides priority access to pregnant women in both general and private 
programs.53
  Indiana law prohibits a medical provider from releasing information about a pregnant 
woman’s drug or alcohol test without her consent.54
RECOMMENDATION: States should provide evidence-based medical care 
to incarcerated populations, including continuing, initiating and ensuring 
access to MOUD. States should remove criminal and other penalties for 
pregnant, postpartum, and parenting women for whom MOUD is part of 
their treatment for an opioid use disorder.
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F. Ensure continued access to MOUD
Individuals with an SUD are diverse in their treatment needs and circumstances, and best 
practices continue to point to the need to provide as many therapies, treatments, and options 
as possible for providers and patients while mitigating unnecessary barriers or conditions to 
receiving care.
Prevent counseling/psychosocial supports from creating a barrier to receiving MOUD.
Counseling and psychosocial supports have been shown to be beneficial to individuals in 
SUD treatment, but the National Academy of Sciences and others have concluded that if it is 
not possible for people to participate in these services, it remains valuable to provide them 
with medication alone. Increasingly, states are eliminating “hard” requirements that Medicaid 
beneficiaries engage in counseling as a condition of receiving MOUD and, instead, are focusing 
on how to promote and expand use of counseling.55 This shift reflects guidance from ASAM 
that an individual’s inability or decision not to engage in counseling “should not preclude 
or delay pharmacological treatment of opioid use disorder, with appropriate medication 
management.”56
For example, states such as New York now explicitly prohibit providers from excluding clients 
from receiving MOUD if they do not engage in psychosocial treatment.57 Instead, providers 
are encouraged to engage clients in any services deemed necessary, including by using 
peer services, rather than by making their access to MOUD contingent on engagement in 
psychosocial services. Similarly, Virginia has moved to providing full clinical discretion to 
providers to determine the circumstances under which access to MOUD should be linked to 
participation in counseling.58
Ensure that polysubstance use (including the use of benzodiazepines) is not a reason to 
discontinue an individual’s treatment with MOUD.
With the opioid epidemic evolving more fully into a polysubstance use epidemic, the issue 
increasingly arises as to whether someone who is using drugs for non-medical purposes (eg, 
prescription opioids, cocaine, methamphetamine, heroin) should be allowed to continue 
on MOUD. Historically, it has been common practice to require that individuals not use any 
substances, as measured by periodic urine screens, as a condition of receiving MOUD. Now, 
however, there is compelling evidence that it is safer and leads to better long-term outcomes, 
including decreased mortality, if clients remain on MOUD even if they still are using other 
substances.
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For example, New York’s guidance to providers on how to handle continued substance and 
polydrug use reflects this approach. It explains that MOUD should not be discontinued 
and clients should not be administratively discharged from treatment solely on the basis of 
continued substance use and/or polydrug use. Also, policies that summarily exclude individuals 
from being admitted because of polysubstance use are not permitted. Rather, providers are 
expected to work with clients over time to engage them in addressing their ongoing substance 
use, using harm reduction principles and motivational interventions, including using their 
clinical judgment to withhold individual doses of full opioid agonist medications if someone is 
intoxicated or appears sedated.59 North Carolina provides similar guidance.60
Similarly, the US Food and Drug Administration recently clarified that it is better practice 
and safer for clients to start and/or continue MOUD even if they are using benzodiazepines 
or similar drugs rather than leave the substance use disorder untreated, because “the harm 
caused by untreated opioid addiction can outweigh these risks.”61
Ensure that individuals entering residential treatment have access to MOUD.
ASAM clinical practice guidelines recommend that individuals in treatment for SUD have access 
to MOUD at all levels of care, including residential levels of care. To facilitate access to MOUD, 
residential facilities can either provide MOUD directly or establish linkages to MOUD providers. 
Residential treatment without MOUD for individuals with an SUD places them at greater 
risk of overdose following their departure from treatment. Despite the evidence,62 many 
residential treatment facilities do not offer any MOUD; 
in 2017, 60% of residential treatment facilities did not 
offer any MOUD, and only 1.3% offered all forms of 
MOUD.63 Additionally, residential treatment facilities 
may bar admission to individuals with an SUD who 
are on MOUD, which forces them to choose between 
continuing on MOUD or entering residential treatment.
States can take steps to ensure that individuals entering residential treatment have access to 
MOUD. For example, states can follow Missouri’s example and require residential treatment 
facilities to offer or arrange for MOUD as a condition of certification and Medicaid contracting.64 
California law bars residential treatment providers from denying admission based on an 
individual’s ongoing use of MOUD, and its Medicaid program requires all residential treatment 
facilities, in order to obtain licensure and certification, to offer or arrange for access to MOUD.
In 2017, 60% of residential 
treatment facilities did not 
offer any MOUD, and only 
1.3% offered all forms 
of MOUD.
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RECOMMENDATION: States should ensure that public and commercial payers 
eliminate treatment policies that impede access to MOUD, such as policies that 
condition access on participating in counseling or abstaining from use of other 
drugs. Residential treatment facilities should be required to ensure access to 
MOUD for new and current patients as a condition of receiving public funding.
G. Maintain COVID-19-driven changes that expand access to evidence-
based treatment
During the COVID-19 public health emergency (PHE), the federal government and some states 
have provided increased flexibility to enable individuals with an SUD to access MOUD and 
other treatment options, providing increased flexibility to initiate and continue treatment 
for an SUD. These changes include giving states discretion to allow OTPs to provide a 28-day 
take-home supply of methadone to stable patients and a 14-day supply to those who are less 
stable but still able to safely handle take-home doses, subject to the treating physician’s clinical 
determination. The federal government and states also have acted to promote telehealth, with 
the federal government allowing initiation of buprenorphine for the first time via telehealth 
and telephone, and states adopting a broad array of policies to promote and pay for care 
delivered via telehealth. Of particular note, 26 states currently allow audio-only behavioral 
health calls during the COVID-19 PHE to be reimbursed under Medicaid, a particularly 
important policy for low-income people with an SUD who may otherwise lack the capacity to 
participate in telehealth.65,66
Early evaluations suggest that the policies have helped to maintain or even expand access to 
treatment without ill effects on clients. For example, Rhode Island has worked with clients and 
law enforcement to determine that increased take-home dosing has not resulted in higher 
rates of adverse events such as diversion and opioid-related deaths.67 Similarly, Massachusetts 
has gathered data on take-home doses and found minimal incidents of diversion, even though 
nearly all patients now are receiving a 28-day supply of methadone.68 While some providers 
and clients continue to prefer in-person treatment, early reviews suggest that the easing of 
access restrictions on MOUD and greater use of telehealth have helped mitigate some of the 
impact of COVID-19 on treatment for SUD.69 Going forward, it will be important to continue to 
monitor the impact of these policies and, if proved effective and safe, to maintain them in the 
post-COVID-19 era.
RECOMMENDATION: States should evaluate policies adopted during the 
COVID-19 public health emergency and make permanent those that have proven 
effective in enhancing access to MOUD.
2020 National Roadmap | 25
III. Enforce mental health and substance use 
disorder parity laws
Parity is still a work in progress, but 2020 saw several important developments indicating that 
additional state legislatures and regulatory agencies are committed to achieving equal access 
to mental health and SUD treatment:
  Six more states passed parity laws in 2020, including states as politically diverse as Arizona, 
Indiana, Maryland, and Oklahoma. Those states join eight others that have passed parity 
laws since 2018. The trend is likely to continue, with another eight states considering parity 
bills in 2020 that likely will be taken up again in 2021.
  A growing number of state insurance regulators are using oversight tools, ranging from data 
calls to attestation requirements to market conduct exams, to monitor compliance. While 
full-scale exams are a proven method for assessing compliance, they require considerable 
resources and involve retrospective reviews, causing some states to look at more nimble 
approaches such as New York’s requirement that insurers self-assess and report on their 
compliance prospectively.
  The NAIC established a new standing work group on parity70 to provide an ongoing forum 
for state regulators to share information and develop common strategies for enforcing 
parity. Thirty states joined the work group, and despite the pandemic, the group has held 
four meetings since March and is expected to continue moving toward providing strong 
guidance to states.
A. Make parity laws more comprehensive
Exhibit 13. Pennsylvania adopts tougher parity laws
Pennsylvania Governor Tom Wolf signed two new mental health and SUD parity laws on 
October 30, 2020 that he said would “strengthen our already robust efforts.” The new laws 
require insurers to fully document their compliance with parity standards and make that 
documentation available to the Pennsylvania Insurance Department (PID) upon request.
“Our exams and investigations, as well as analysis of consumer complaints, 
indicate that mental health parity noncompliance persists. We appreciate the 
legislative leaders that worked with PID, insurers, and consumer advocates to 
help strengthen Pennsylvania’s parity framework through this legislation. The 
legislation will result in greater compliance across insurance companies and 
improve consumer access to understandable coverage information.”
—Pennsylvania Insurance Commissioner Jessica Altman commenting on new parity laws
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Recently enacted state parity laws, many of which build on less prescriptive parity laws 
enacted a decade ago, focus on both insurer reporting requirements and regulatory oversight 
procedures. The recent parity laws set out more stringent standards for insurers to self-
assess their compliance and for regulators to exercise more oversight. While the laws require 
market conduct exams and other forms 
of retrospective review, recent laws 
increasingly emphasize prospective 
action by insurers to identify and correct 
unequal treatment rather than wait to 
penalize parity violations after the fact. 
The shift from “back-end” reviews to 
“front-end” assessments recognizes that 
finding and correcting violations several 
years after the fact is less effective and 
more expensive than proactively requiring 
insurers to demonstrate their compliance 
through annual reports or when seeking 
rate and form approval for new products.
Insurer annual reports. In March 2020, Indiana legislators passed HB 1092, which requires 
insurers to annually submit a report and analysis to the Indiana Department of Insurance 
that demonstrates compliance with parity laws, including descriptions of the processes used 
to develop medical necessity criteria and nonquantitative treatment limitations (NQTLs)71 
for mental health and SUD benefits as compared with the processes used for medical and 
surgical benefits.72
Oklahoma passed a similar law in May 2020, requiring health plans to submit an annual report 
with the following elements:73
  A description of the processes used to develop or select medical necessity criteria for mental 
health/substance use disorder (MH/SUD) benefits and the corresponding processes for 
medical and surgical benefits
  Identification of all NQTLs applied to mental health/substance use disorder (MH/SUD) and 
medical/surgical benefits
  A comparative analysis that demonstrates that the medical necessity criteria and NQTL limits 
are comparable for MH/SUD and medical/surgical benefits
  An indication that the insurer is compliant with Mental Health Parity and Addiction Equity 
Act of 2008 (MHPAEA) requirements
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“This is kind of where cancer was a lot of years 
ago when the coverage wasn’t happening. 
Today, it’s just standard coverage. I think it’s 
very important that we do this to help those 
that truly are dealing with mental health. I think 
it’s one of those that could actually save lives.” 
—Oklahoma Sen. John Haste, R-Broken Arrow, 
the Senate co-author of SB 1718
Comparative analysis of NQTLs. Many of the 
new laws draw from a model law developed 
by the American Psychiatric Association (APA) 
that includes detailed provisions related to 
NQTLs, which present more difficult challenges 
when trying to compare standards for medical/surgical coverage to standards for MH/SUD 
coverage. NQTLs include utilization management techniques, such as prior authorization and 
step therapy, but also network participation and reimbursement policies for providers. As 
states wrestle with developing templates and other tools for insurers to use in documenting 
their own compliance, many Departments of Insurance (DOIs) are turning to the NAIC work 
group, which is building out those templates to ensure that insurer compliance reviews look at 
policies and procedures as well as the application of those policies and procedures.
Maryland enacted parity legislation in May 2020 requiring insurers to conduct parity analyses 
on their highest-selling products, and also directing the Maryland insurance commissioner to 
use the NAIC’s data collection tool for NQTL comparative analysis as the basis for a standard 
insurer reporting form.74
Regulatory oversight procedures. The new laws typically charge state insurance regulators 
with enforcing federal parity laws and regulations and using the full continuum of regulatory 
tools to ensure parity. Among the regulatory duties enumerated are developing standard 
insurer reporting forms, actively reviewing insurer reports and addressing deficiencies, 
responding to and evaluating consumer complaints, reviewing parity compliance during the 
rate and form approval process, performing market conduct examinations, and reporting back 
to the legislature on compliance and enforcement efforts.
Arizona amended its parity law in March 2020 to require detailed insurer reporting on NQTLs 
and other comparative analyses, and directs the Arizona Department of Insurance (DOI) to 
review insurer reporting and, among other things, develop a webpage that explains insurer 
“This is kind of where cancer 
was a lot of years ago when the 
coverage wasn’t happening. 
Today, it’s just standard coverage. 
I think it’s very important that we 
do this to help those that truly 
are dealing with mental health. 
I think it’s one of those that could 
actually save lives.”
—Oklahoma Sen. John Haste, R-Broken 
Arrow, the Senate co-author of SB 1718
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obligations and how consumers can file complaints about alleged insurer violations.75 
The webpage must include a DOI summary of its analysis of insurer reporting, “including 
any conclusions regarding industry compliance.” The statute also includes protections for 
proprietary information and has specific provisions applicable to multitiered networks and 
prescription drug benefits.
Medical standards. California enacted a sweeping 
new parity law in September 2020 that expands 
coverage and requires insurers to rely on medical 
experts when making coverage decisions. The 
new law expands the state’s preexisting parity 
law to cover medically necessary treatment for all 
mental health and substance use disorders listed 
in the most recent edition of the Diagnostic and 
Statistical Manual of Mental Health Disorders (DSM), and tightens requirements as to the use 
of generally accepted medical standards for developing and applying “medical necessity” 
criteria to make coverage decisions.76 More specifically, the law requires insurers to use 
evidence-based and expert-recognized criteria for medical necessity to ensure that treatment 
decisions are based on medical expertise rather than insurer-designed standards.77 The 
new law addresses some key deficiencies identified in a recent report78 on California’s parity 
challenges, but the report also suggests that California’s health insurance regulators should 
strengthen their oversight of insurers’ utilization management practices, including network 
participation requirements. The report pointed to 
lower reimbursement rates for behavioral health 
providers,79 as well as onerous payment procedures 
and burdensome contracting terms, as reasons 
why behavioral health networks are not necessarily 
in parity with medical/surgical networks.
“SB 855 is vital legislation in the face of a worsening 
mental health and addiction crisis exacerbated 
by the current COVID-19 pandemic,” said Ricardo 
Lara, California insurance commissioner, on June 
10, 2020.80 “SB 855 will put in place reasonable and 
necessary reforms to guarantee that Californians 
have access to life-saving mental health/substance 
use disorder (MH/SUD) services.” Commissioner 
California enacted a sweeping 
new parity law in September 
2020 that expands coverage 
and requires insurers to rely 
on medical experts when 
making coverage decisions.
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Lara also emphasized that “SB 855 would create minor costs to the California Department of 
Insurance: $3,000 in financial year 2020-21, associated with the slight increase in reviewing 
form filling.”
According to California Sen. 
Scott Wiener, the prime sponsor 
of SB 855: “Mental health care 
is essential to a person’s overall 
health, and today, we reaffirmed 
that people must have access 
to care for mental health and 
addiction challenges. California’s 
mental health parity law has huge 
loopholes—which the insurance 
industry has used to deny critically 
important care—and today that 
loophole was closed. SB 855 sends 
a powerful message to the nation 
that California prioritizes the 
mental health of its residents.”
RECOMMENDATION: States should strengthen their mental health and 
substance use disorder parity laws based on proven models, including 
California’s Senate Bill 855 and models supported by key stakeholders such 
as the American Psychiatric Association and the Kennedy Forum.
B. Use the full continuum of regulatory tools
States are using a variety of approaches to assess and enforce compliance, many of which go 
beyond the requirements contained in the new parity laws.
Attestation. The New York Department of Financial Services (DFS) is developing a 
comprehensive regulatory strategy with insurer self-assessment and attestation as the 
foundation for prospective enforcement efforts. The regulations, which became final on 
October 1, 2020, require insurer compliance programs to establish corporate governance 
for parity compliance, identify discrepancies in coverage of services for the treatment of 
mental health conditions and substance use disorder, and ensure appropriate identification 
“Mental health care is essential to a 
person’s overall health, and today, we 
reaffirmed that people must have access 
to care for mental health and addiction 
challenges. California’s mental health 
parity law has huge loopholes—which 
the insurance industry has used to deny 
critically important care—and today 
that loophole was closed. SB 855 sends 
a powerful message to the nation that 
California prioritizes the mental health of 
its residents.”
California Sen. Scott Wiener (D-San Francisco), 
the prime sponsor of SB 855
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and remediation of improper practices. To expedite enforcement, the regulations require 
insurers to attest to their compliance on an annual basis and, further, to make their compliance 
documentation readily available to DFS upon request.81
The Pennsylvania Insurance Department proposed a similar attestation requirement in early 
2020 and recently completed a public comment period on the regulation, which would 
establish mental health and SUD parity compliance program requirements similar to those 
for New York’s program. The proposed regulation requires that such compliance programs 
establish corporate governance for parity compliance, identify discrepancies in coverage 
of services for the treatment of mental health conditions and SUD, and ensure appropriate 
identification and remediation of improper practices.82
Data calls. Washington’s Office of the Insurance 
Commissioner used federal grant funds to collect 
data from insurers and have it analyzed by 
clinicians at the University of Washington (UW). 
In a December 2019 report, the UW clinicians 
reviewed and analyzed the development, 
substance, and application of Washington 
commercial health plans’ prior authorization and 
utilization management policies and procedures. The report noted that this particular study 
may be “one of the most in-depth and comprehensive evaluations of parity to date,” and 
found that based on market scan data, many of the carriers that participated made sincere 
efforts to implement parity between medical/surgical and MH/SUDs, especially through the 
specific policies outlined to ensure parity for individuals with OUDs and policies implemented 
to ensure access to potentially life-saving treatments. However, overall, information collected 
on the real-world operationalization of policies and procedures was limited through this first 
analysis, with some of the information provided being inconsistent, incomplete, or vague. The 
report calls for further data collection and analysis using claims data to assess key quantitative 
treatment limitations (QTLs) and NQTLs, and further study of the actual rates and use of MH/
SUD benefits across different insurance plans and products.
While conducting a data call and analyzing the findings can be an extensive and involved 
process, the findings from this report demonstrate, in a way that other assessments are 
unable to identify, the value of detailed data calls as a tool for assessing the implementation 
and operationalization of parity in the commercial insurer space, with the ability to examine 
existing parity gaps at a more granular level while also understanding the specific challenges 
insurers face in implementing parity.
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Ombudsman offices. In 2019, Colorado 
established the Office of the Ombudsman for 
Behavioral Health Access, which released its 
first annual report in September 2020. This 
independent office helps Coloradans resolve 
behavioral health access and coverage issues, 
including helping consumers with parity 
complaints and reporting on parity enforcement. 
In its first year, the Office of the Ombudsman 
focused on developing formal practices and processes for consumer complaints and new 
cases. The report emphasizes that, as the office began opening new case calls, many of 
the cases were complex and time-consuming and required the engagement of multiple 
stakeholders to resolve reported issues, which extended beyond basic behavioral health access 
and coverage and engaged areas of housing, justice, and child welfare. The office also worked 
to establish connections with liaisons in various state and federal agencies, including the state’s 
Division of Insurance, Department of Health Care Policy and Financing, and the state’s Office 
of Behavioral Health, to identify, report, and prioritize behavioral health parity and coverage 
issues. Behavioral and mental health ombudsman programs and offices are growing in number 
across the country83 and are likely to continue to play a role across states in advocating and 
ensuring parity and compliance for patients with MH/SUD needs.
Rate and form reviews. As states consider the most efficient ways to ensure parity 
compliance, many are focusing on the annual rate and form review process that has become 
more standardized in the 47 states that have been certified by the Center for Consumer 
Information and Insurance Oversight (CCIIO) to conduct rate reviews for products to be sold 
through the ACA Marketplaces. Since rate review (how much the insurer proposes to charge for 
a given product) is integrally related to form review (what benefits are covered by each given 
product), many states use their annual ACA process to require insurers to demonstrate that 
the benefits they cover in their ACA and non-ACA products comply with parity requirements, 
including NQTLs.
North Carolina issued a new and more comprehensive parity checklist in May 2020 that 
requires insurers to engage in detailed comparative analysis of MH/SUD and medical/surgical 
benefits to demonstrate parity. The new North Carolina requirements also include a new 
attestation form. North Carolina is an active state for market conduct exams as well, but the 
more rigorous rate and form reviews should allow for early detection of problems and allow 
the DOI to target examination resources more effectively.84,85
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The type of “enhanced attestation” required by the North Carolina Department of Insurance is 
the basis for a recommendation by the AMA, ASAM, and the American Psychiatric Association 
(APA) for all DOIs to require health insurers to demonstrate compliance with the law at the time 
of rate and form filing. The AMA, APA, and ASAM believe that the obligation of demonstrating 
compliance with the law is something payers can and should do. Because the MHPAEA is a 
comparative law, payers should do the comparisons to analyze whether they are in compliance 
with the law. Requiring prior comparative analysis can help streamline oversight, can help 
payers identify gaps, and, most important, may help ensure patients have the coverage 
required by the law.86
Market conduct exams. A December 2019 US 
Government Accountability Office (GAO) report 
found that market conduct examinations are a 
leading regulatory strategy, and examination 
findings are frequently featured on DOI websites 
as leading indicators of noncompliance with 
parity requirements. Pennsylvania has been conducting parity examinations for several years, 
and much of what Pennsylvania regulators learned through those exams has helped shape the 
agenda for the NAIC’s parity working group.
At the same time, exams have their limitations, including time lags, with exams often looking 
back two or more years, and procedural requirements, such as time-consuming negotiations 
over corrective action plans. Indeed, a common thread in the exams described below is that 
exams started several years ago are still in process. These drawbacks help explain why the 
NAIC’s market conduct committee has been expanding its continuum of regulatory tools over 
the past 15 years, and why the NAIC parity working group has focused much of its attention on 
prospective reporting tools.
With these caveats, exam activity was an important feature of the parity landscape in 2020. In 
February 2020, the New Hampshire Insurance Department published market conduct exams 
on the state’s three largest insurers, based on reviewing insurer practices in 2016 and 2017. 
In the exam report, the state concluded that there was parity noncompliance in the areas of 
benefit design, network design, grievances and appeals processes, claims handling, provider 
reimbursement, step therapy, and prior authorization for MOUD/SUD medications. The exams 
further concluded that Anthem and Harvard Pilgrim did not provide sufficient information 
to demonstrate that they meet the comparability requirement and would be required to 
develop compliance assurance plans with the state and to undergo a two-year monitoring and 
reporting period to ensure implementation of initiatives aimed at improving MH/SUD provider 
The AMA, APA, and ASAM 
believe that the obligation of 
demonstrating compliance with 
the law is something payers can 
and should do.
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networks and address other areas of noncompliance. After the two-year monitoring period, 
if the plans are determined to be compliant, the department will issue an updated report; if 
noncompliant, the department will begin a follow-up examination.
The Rhode Island Office of the Health Insurance Commissioner (OHIC) published three exam 
reports in 2020 covering UnitedHealthcare (UHC),87 Neighborhood Health Plan (NHPRI),88 and 
Tufts.89 In the exams, which were commenced in early 2015, the state concluded that there 
were parity violations in clinically inappropriate or inadequate utilization review criteria and 
practices, coercive utilization review practices, denials based on subjective conclusions, notices 
of adverse benefit determination, noncompliance with decision and appeal time frames, 
inappropriate denials of coverage, and more. For all three plans, the commissioner ordered 
the plan to submit a proposed plan of correction to address the recommendations to OHIC 
for review and approval. For NHPRI and Tufts, in lieu of a penalty payment, the commissioner 
ordered the plans to make contributions to a fund created by the OHIC at the Rhode Island 
Foundation to support behavioral health prevention services and early intervention programs 
in the state, totaling $330,000 over the next three years for NHPRI and a one-time contribution 
of $150,000 for Tufts. For UHC, the commissioner ordered both a penalty payment of $350,000 
by April 15, 2020, and a contribution of $2.85 million to the Rhode Island Foundation to 
improve the behavioral health system infrastructure in the state. Previously, OHIC had required 
the Rhode Island Blue plan to make a $5 million community contribution in lieu of a penalty in 
2018 for similar violations as determined by the state.
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Illinois announced in July 2020 more than $2 million in fines against insurers for parity 
violations found during market conduct exams from 2015-2017. Penalties were levied against 
CIGNA, UnitedHealthcare, HCSC (parent company of Blue Cross Blue Shield) and Celtic. The 
state said its $582,000 penalty against CIGNA Healthcare was “for failing to use medical 
necessity guidelines required by statute and the American Society of Addiction Medicine 
(ASAM), and not allowing providers to request an exception to the company’s step therapy 
requirement for prescriptions.” The state said its penalty against UnitedHealthcare was for 
its failure “to use ASAM guidelines, requiring prior authorization from the company before a 
provider can prescribe the patient buprenorphine to help fight substance use disorder, and 
requiring prior authorization for prescribing certain ADHD medications.”90
The 2019 roadmap noted that the Colorado insurance commissioner had rejected market 
conduct examinations conducted by contracted examiners because he was not satisfied 
that the examiners had asked the right question on parity. In a 2020 report, the Colorado 
DOI reported that it had initiated a new round of exams, though the process will remain 
confidential until the exams are completed.91
Exhibit 14. Pennsylvania: UnitedHealthcare’s exam findings
In 2019, Pennsylvania released the findings of a market conduct examination that covered 
January 2015 through March 2016 data and concluded that UnitedHealthcare was in 
“extensive noncompliance with mental health parity and prompt pay laws, as well as 
concerns regarding the company’s coverage for services relating to autism spectrum 
disorders and substance use disorders,” resulting in a civil penalty of $1 million to the 
insurer, in addition to an $800,000 commitment for public outreach activities and restitution 
payments to its consumers who had claims wrongly denied, had overpaid in out-of-pocket 
expenses, or had accrued interest on delayed claims.92
While state DOIs play the largest role in regulating health insurance carriers, state attorneys 
general also can play a powerful role in enforcing parity laws. For example, New York 
Attorney General Letitia James published a report focused on investigations into health plans’ 
compliance with federal and state parity that resulted in $3 million in fines and $2 million 
for patient reimbursement. The report focused on Anthem, Beacon Health Options, Cigna, 
EmblemHealth, Excellus, HealthNow, and MVP.93 In Massachusetts, Attorney General Maura 
Healey determined that there were parity and other violations by Harvard Pilgrim Health 
Care and United Behavioral Health d/b/a Optum; Fallon Community Health Plan and Beacon 
Health Strategies; AllWays Health Partners; Blue Cross Blue Shield of Massachusetts (BCBS); 
and Tufts Health Plan.94 We encourage other state attorneys general to consider making parity 
enforcement a priority for their offices.
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Exhibit 15. GAO report finds parity activity in nearly all states95
Nearly all states reported to the GAO that they review insurer documentation for MH/SUD 
parity requirements and compliance before approving the sale of plans to consumers in 
these states, particularly by looking at financial requirements, QTLs, and NQTLs; however, 
state oversight of insurers after consumers enroll in plans is varied, with 27 states 
reporting that they have conducted some type of review related to MH/SUD parity after 
consumers enroll. The types of reviews states conduct vary and include:
  Targeted reviews based on consumer complaints or other information. According 
to GAO’s survey, in 2017 and 2018, 38 states tracked MH/SUD parity complaints (which 
can be submitted by consumers, providers, or advocates), and 12 states conducted 
targeted reviews that focused on specific issuers or particular parity concerns, largely 
initiated by consumer complaints. States expressed that targeted reviews are more 
frequently used than more comprehensive market conduct examinations because 
they are focused on a specific issue, rely on more recent data, and are generally less 
time consuming to conduct.
  Broader market conduct examinations. Nearly all states perform market conduct 
examinations, but states have not routinely included a review for MH/SUD parity 
compliance as part of the examinations. Of 18 states that reported to GAO that they 
perform routine market conduct examinations (every three to five years), only nine 
reported that they always include a review of MH/SUD parity compliance. However, the 
NAIC has developed guidance on MH/SUD parity for its Market Regulation Handbook 
to encourage more states to include these parity reviews in their market conduct 
examinations.
  Statewide comprehensive reviews of all issuers. Some states reported that they 
have conducted reviews of all issuers in their states as part of their MH/SUD parity 
oversight and compliance efforts after consumers enroll in plans. Some states are 
doing this through legislative requests, and others are conducting such reviews 
through grant funding.
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RECOMMENDATION: State insurance regulators should pursue a full 
continuum of actions for assessing and enforcing mental health and 
substance use disorder parity, including requiring insurers to prospectively 
analyze and attest to their compliance, analyzing consumer complaints, 
conducting rate and form reviews, issuing data calls, and performing market 
conduct exams. Legislatures should ensure that state parity laws are based 
on the strongest models, and DOIs and Attorneys General can each play a 
role in enforcing state laws.
C. Share resources through the NAIC parity working group
The NAIC officially launched the MHPAEA Working Group on March 9, 2020, charging it with 
making “recommendations regarding NAIC strategy and policy” with respect to developments 
related to federal parity law and coordination with the states and federal agencies. 
The working group is also charged with providing “supplemental resources to support 
documentation and reporting” for market regulation purposes. Thirty states have joined the 
working group, which is led by Pennsylvania and Washington and has met four times.
The working group has already been instrumental in supporting states that are in the process 
of implementing new state parity laws or exercising their market oversight authority to require 
more detailed reporting by insurers. For example, Texas’ release of a proposed reporting 
template and Oklahoma’s implementation of a new parity law96 both benefited from the work 
of the parity group.
The working group’s focus on reporting templates 
started with the more straightforward QTLs and 
moved to NQTLs, with prescription drug coverage 
and provider reimbursement policies identified 
as particularly important and challenging areas. 
The group also has heard from a wide range of 
stakeholders, including America’s Health Insurance 
Plans, which encouraged the group to compile a 
variety of approaches to the templates, and from 
NAIC consumer representatives, who asked the 
group “to operationalize NQTL compliance analysis 
in a way that is accessible to consumers.”
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Exhibit 16. NAIC principles for parity enforcement
The MHPAEA Working Group adopted the following principles:
  MHPAEA regulations are sequential and interrelated.
  At its core, MHPAEA is about addressing discriminatory differences in how plans/
issuers apply limitations to MH/SUD benefits.
  Parity as a concept, and as contemplated in the laws and regulations, requires 
comparability analyses:
 – For quantitative measures, comparability is measured as a function of expected 
claims dollar amounts ratios.
 – For nonquantitative measures, comparability is measured as a comparison of the 
factors and standards used to arrive at the limitations to be applied.
  Analyses must be completed at inception and on an ongoing basis, ie, as written and 
in operation.
RECOMMENDATION: State insurance regulators should participate in the 
NAIC’s MHPAEA Working Group by sharing best practices from their state, 
using templates and other tools developed by the Working Group, and 
following best practices from other states.
2020 National Roadmap | 38
IV. Ensure access to addiction medicine, 
psychiatry, and other trained physicians
Patients in need of OUD treatment should have 
timely access to addiction medicine physicians 
and other health care professionals who treat 
OUD and mental health disorders. This includes 
primary care physicians trained to provide 
treatment for an OUD. Medicaid officials and 
insurance regulators can expand patients’ 
access to care by enforcing network adequacy 
requirements and taking other actions to 
support providers, such as increasing payment 
for behavioral health and SUD providers and 
ensuring payment parity for BH/SUD providers 
compared with medical/surgical providers. These issues are especially important now, given 
early state and local data suggesting increases in opioid- and drug-related overdose and death 
during the COVID-19 pandemic,97 which emphasizes the need to ensure adequate access to 
and support for critical addiction specialists other physicians and health care professionals.
Prior to the COVID-19 pandemic, states were expanding Medicaid provider networks for 
the continuum of SUD services as part of their 1115 SUD waivers. As states think more 
systematically about network standards that address the various types of outpatient and 
inpatient care needed to treat SUDs, questions about ensuring quality of care must be 
addressed. The challenges are most acute with residential treatment, which is much more 
expensive than office-based treatment, and can attract low-quality or even fraudulent 
providers if not closely monitored.
Other important developments in 2020 include the rapid expansion of telehealth in response 
to COVID-19 and stronger parity laws that require behavioral health and SUD providers to be 
reimbursed in parity with medical/surgical providers.
A. Measure and monitor provider network capacity
States should strengthen their ongoing efforts to assess network adequacy through annual 
network reviews and ongoing monitoring of consumer complaints and other indicators of 
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impeded access to providers. A robust network adequacy program starts with strong and 
objective statutory and regulatory requirements and “front-end” network reviews as part 
of approving insurer product filings, to ensure that consumers are being offered plans that 
have adequate numbers of accessible addiction medicine physicians, psychiatrists, and other 
mental and behavioral health care professionals accepting new patients. A full network 
adequacy program also includes “back-end” compliance audits or market conduct exams to 
regularly review adequacy and access, as well 
as established processes for collecting and 
responding to consumer complaints regarding 
access challenges. While many states use some 
combination of front- and back-end network 
adequacy reviews, all states have an opportunity 
to do more in this area.
Quantifiable standards are important. As pointed out by health policy experts at 
Georgetown University, “meeting network adequacy requirements does not automatically 
guarantee that a plan provides enrollees with access to in-network MH/SUD providers 
comparable to other medical providers.”98 A critical first step to ensuring access is to evaluate 
the current capacity of provider networks to treat enrollees with OUD. To this end, insurance 
regulators and Medicaid officials should require insurers to identify how many physicians 
and physician extenders are currently able to provide buprenorphine (a common form of 
MOUD) in-office for the treatment of OUD, how many patients those physicians can treat, 
and how many patients they currently are treating. Otherwise, there is a risk that a plan may 
have a network that appears adequate on paper when, in fact, patients do not have access to 
participating providers with 
a DATA 2000 “x-waiver” to 
the extent promised by 
the health insurer. Insurers 
could apply a similar 
approach to measuring 
the sufficiency of OTPs for 
methadone dispensing, 
residential treatment 
providers, and other SUD 
providers so that insurers 
understand the capacity of 
network providers.
While many states use some 
combination of front- and back-
end network adequacy reviews, 
all states have an opportunity to 
do more in this area.  
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Exhibit 17 shows an aggregate increase of 32% in the number of physicians able to provide 
buprenorphine from May 2019 to October 2020. While this represents significant progress, 
it is likely that states that perform the suggested analysis in this section will find substantial 
shortages in some geographical areas. In addition, it is critically important that provider 
networks are culturally relevant and diverse in order to reflect the communities they serve. 
Addressing the shortages of Black/African American x-waivered physicians across states can 
help address the significant disparities in access to buprenorphine for Black/African American 
individuals with an SUD.
Exhibit 17. SAMHSA national data on waivered health care professionals, May 2019 
to November 2020
Figure A. SAMHSA buprenorphine 
practitioner and program data, May 201999
Figure B. SAMHSA buprenorphine 
practitioner and program data, November 2020100
Exhibit 18. Colorado regulators intensify focus on network adequacy in response 
to new state law
The Colorado Division of Insurance published a report on June 1, 2020 that detailed the 
Division’s comprehensive efforts to enforce new parity laws, including stronger network 
adequacy standards designed to correct deficiencies in network coverage for behavioral 
health highlighted in a November 2019 Milliman report. Among other findings, the 
Milliman study found that enrollees were 7.95 times more likely to use an out-of-network 
behavioral facility than an out-of-network medical/surgical facility.
“It is worth noting that the Division does not typically involve itself with provider-
carrier relations, but it has done so given the intricacy of provider relations to parity 
compliance in areas such as credentialing processes, network adequacy standards, and 
reimbursement rates.”
—Excerpt from a Mental Health Parity Implementation and Enforcement Report by the 
Colorado Division of Insurance to the Colorado Legislature, June 2020101
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In response to a 2019 state law, the Colorado DOI amended its network adequacy regulations 
to include new standards for evaluating the adequacy of mental health, behavioral health, and 
SUD networks. The requirements were part of a larger package that strengthened the DOI’s 
parity oversight across the board. The DOI cited a 2019 Milliman report that found Colorado 
consumers eight times more likely to use out-of-network facilities for behavioral health than for 
medical/surgical treatment.102
RECOMMENDATION: State insurance regulators and Medicaid officials 
should require all health carriers to publicly disclose the following:
  The number of physicians and other health care professionals in each 
network who have an x-waiver to provide buprenorphine in-office for the 
treatment of opioid use disorder
  The number of patients those waivered providers are able to see (ie, the 
patient limit allowed by the waiver)
  The number of patients currently being treated with buprenorphine
RECOMMENDATION: States should address the shortage of Black, Hispanic, 
American Indian, and other minoritized populations of x-waivered 
physicians across states to ensure network adequacy in areas that are 
disproportionately impacted by SUD.
B. Build critical infrastructure
Physicians and other critical MOUD providers who care for patients with an SUD must be 
equipped with the appropriate support in order to meet the needs of the SUD population. A 
“hub-and-spoke” model, first developed in Vermont to help address the need for patients to 
have access to a wide range of medical and social and other behavioral care services, offers 
providers technical assistance and expert guidance, as well as a mechanism for referring 
particularly complex patients. The hub-and-spoke model has now been adopted or modified 
by several other states, including Pennsylvania, North Carolina, and others.
Enhancing access through hub-and-spoke models. Pennsylvania’s hub-and-spoke 
model centers on an addiction specialist, who serves as the “hub,” providing expertise and 
guidance to primary care physicians, or the “spokes,” who practice in rural and underserved 
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communities across the state. These primary care providers provide direct patient care and 
prescribe MOUD where appropriate, and link patients to drug and alcohol counseling in their 
communities. Having the addiction specialist “on hand” to support primary care providers in 
the community ensures that primary care providers are equipped with the supports needed to 
ensure necessary treatment is available to residents seeking care and treatment. The network 
includes 45 Centers of Excellence (COEs), which have served 32,500 people with an OUD 
through Medicaid since 2016. There also are 14 Pennsylvania Coordinated Medication Assisted 
Treatment (PacMAT) programs participating in the hub-and-spoke model to provide evidence-
based treatment to people where they live, and since 2018, these centers have helped over 
6,000 people receive MOUD103; in 2019, the state committed $26 million to the centers and has 
provided support to a number of other initiatives and programs to continue addressing the 
opioid crisis in Pennsylvania. This year, Pennsylvania’s Secretary of Health, Dr Rachel Levine, 
announced two new health systems intended to build MOUD programs for individuals with 
SUD who are uninsured, underinsured, or privately insured.104
In North Carolina, a collaboration between the 
University of North Carolina at Chapel Hill School of 
Medicine and the Mountain Area Health Education 
Center aims to establish referral relationships with 
community health centers and health departments 
in western North Carolina to develop the hub-and-
spoke relationships needed to expand access to 
MOUD for low-income individuals and connect 
them to other supports and services.105
Having providers that are waivered and trained, particularly in rural areas, are critical to 
implementing these models. North Carolina has taken steps to integrate addiction training, 
including getting the federal DATA waiver to prescribe buprenorphine, as part of standard 
medical education. The North Carolina Department of Health and Human services funded a 
residency training program, which has trained more than 800 current providers and residents, 
as well as incorporated waiver training into more than 30 residency programs in North 
Carolina. Through an initiative led by the N.C. Governor’s Institute, four out of five North 
Carolina medical schools now incorporate waiver training as part of their standard curriculum.
Linking those who experience an opioid-related overdose to treatment. The risk of fatal 
overdose is greatly increased when there is a prior, nonfatal overdose.106,107 Opportunities for 
engagement, therefore, often occur in the emergency department (ED). When a patient arrives 
in a University of Colorado Health System emergency department and is identified as having 
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OUD, a social worker intervenes to conduct an in-depth screening. If clinically indicated and 
if a patient is willing, providers prescribe buprenorphine. A grant from the Colorado Office 
of Behavioral Health assisted in the development of resources to provide “warm handoffs” 
to community providers, according to Denver emergency medicine physician Jason Hoppe, 
DO. In a published study of the program,108 “[f]rom June 1, 2018, through August 31, 2019, 
120 patients opted for ED buprenorphine induction. 61% presented to initial outpatient 
intake appointment and 39% remained engaged in treatment after 30 days.” In a subsequent 
interview, Dr Hoppe said that after two years, of 302 patients identified as needing treatment 
for a substance use disorder, 268 (88%) agreed to initiate treatment, 56% showed up for their 
first appointment, and almost half (45%) were still in treatment at 30 days. “It’s hard work,” said 
Dr Hoppe, “but we’re making progress.”
What worked in Denver, moreover, has been shown to work elsewhere—albeit part of the 
“hard work” involves systemic changes such as ensuring appropriate ED workflow, staffing, 
potential changes in electronic health records, education, and identifying “a network of local 
community ‘fast-track’ providers able to accept patients for next-day appointments,” according 
to a study of buprenorphine induction in the South.109 It took 14 months to put the programs 
together across three different locations, and researchers ultimately reported that, “[o]f the 
727 positive screened patients for non-medical opioid use, 70% were determined potentially 
eligible to receive buprenorphine initiation,” and 231 began treatment with buprenorphine. Of 
that cohort, 77% went to their next-day appointment, and 60% were in treatment at 30 days.
RECOMMENDATION: States should coordinate efforts in communities 
among emergency departments (EDs), health insurance companies, and 
physicians who treat opioid use disorder to ensure that ED health care 
professionals and staff have the education and resources to conduct 
Screening, Brief Intervention and Referral to Treatment (SBIRT) or similar 
screening, initiate buprenorphine, and make appropriate referrals, and that 
there are in-network physicians ready to accept next-day appointments for 
those willing to continue treatment.
Leveraging Medicaid managed care requirements and other state tools to expand the 
provider network. States can hold their managed care organizations (MCOs) accountable 
for rigorous and specific network adequacy requirements in their Medicaid managed care 
contracts, and require that plans reimburse providers at specified rates if necessary, to ensure 
that plan networks are sufficient to meet the needs of Medicaid members with an SUD. For 
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example, Ohio requires its Medicaid MCOs to contract with a minimum number of MOUD 
providers per county and all willing OTPs.110
In addition, states have used Medicaid Delivery System Reform Incentive Payments (DSRIP) 
and SAMHSA grants to increase network capacity for SUD services, including for OTPs and 
other MOUD providers. For example, Washington has leveraged its DSRIP program to support 
capacity and infrastructure investments for SUD treatment providers, including OTPs.111 
SAMHSA’s State Opioid Response (SOR) grants awarded to state and tribal entities are intended 
to support the expansion of evidence-based prevention, treatment, and recovery services 
for OUD and stimulant use. While most of these funds must be used to support direct care 
services, up to 5% can be used to support infrastructure development for providers, including 
training and workforce and IT investments.112 SOR recipients are also required to ensure that all 
eligible providers obtain waivers to prescribe buprenorphine.
RECOMMENDATION: States should meaningfully support community 
hub-and-spoke model programs that expand provider capacity and link 
patients—including Medicaid, commercially insured, and uninsured 
populations—to multidisciplinary care.
RECOMMENDATION: State Medicaid officials should leverage Medicaid 
managed care contracting as a tool to enforce robust network adequacy 
requirements and support the inclusion of racially, ethnically and culturally 
diverse physicians and other health care professionals in those networks.
C. Enforce parity standards to enhance access to in-network care
As discussed in the parity section of this roadmap, parity enforcement will promote stronger 
provider networks. A 2019 study by Milliman found broad inequities in 2017 reimbursement 
rates between MH/SUD providers and medical/surgical providers for office-based 
services.113 These inequities have worsened since 2015, with primary care reimbursements 
found to be 23.8% higher than behavioral health reimbursements, up from 20.8% higher 
reimbursements for primary care versus behavioral health in 2015. Eleven states114 were found 
to have reimbursement rates for primary care office visits that were over 50% higher than 
reimbursement rates for behavioral office visits. By contrast, only four states (Hawaii, Indiana, 
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Mississippi, and Nevada) had provider reimbursements that were more favorable for behavioral 
health office visits than for primary care office visits.
In addition, wide disparities in out-of-network use for behavioral health care compared 
to medical/surgical care were identified,115 with particularly wide disparities for substance 
use disorder care, finding that out-of-network utilization rates for SUD office visits were 5.7 
times those of primary care visits in 2013, and increased in 2017 to 9.5 times those of primary 
care visits. To be clear, unjustified differences in reimbursement rates and unequal efforts 
to incentivize network participation are potential MHPAEA parity violations and should be 
addressed and remediated to promote adequate networks and access for patients with MH/
SUD to in-network care.
The NAIC work group is looking at provider payment as a critical parity issue since lack of parity 
makes it harder for behavioral health providers to participate in insurer networks, which in turn 
forces patients to find out-of-network providers and incur higher cost sharing.
RECOMMENDATION: State regulators should recognize a lack of parity 
between MH/SUD and medical/surgical provider payments as a parity 
violation and ensure that behavioral health and SUD providers are being 
paid at parity under federal and state mental health and SUD parity laws.
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D. Provide federal, state, and local support to SUD providers struggling 
in wake of COVID-19
Even prior to COVID-19, there were 
significant gaps in the number of providers 
available to treat SUD, with only one in ten 
people with SUD receiving treatment. In 
39% (1,228) of counties—representing 18 
million residents—there was not a single 
waivered buprenorphine provider in 2019.
COVID-19 has made things worse, with 
both decreased revenue for SUD providers 
and increased costs in areas such as 
providing personal protective equipment 
(PPE), reconfiguring office space, and 
acquiring telehealth equipment. At the 
same time, state Medicaid programs are 
looking at massive cuts unless they receive 
more federal support. The result could be 
reduced payment rates for SUD providers, 
which would further jeopardize access to SUD treatment. Commercial insurers have helped fill 
gaps in some states where they have benefited from deferred care, but state efforts to broker 
extra-contractual support for providers has been rare and ad hoc.
State activities supporting SUD providers amid the COVID-19 pandemic. COVID-19 has 
posed new challenges for SUD providers, and it is critical that they receive funding during 
the pandemic to prevent closures and other actions that set back efforts to build and expand 
capacity. To that end, states and, to a more limited extent, commercial insurers are taking steps 
to provide funding and technical expertise.
States are providing information and technical assistance to providers so that they can take 
advantage of high-priority federal funding opportunities and understand what programs 
they qualify for and how they can apply for funding support. Montana, for example, sent its 
providers a simplified chart that summarizes when and how they can apply for support out of 
the $175 billion Provider Relief Fund.116 Other states are directly increasing Medicaid payments 
to SUD providers to support them throughout the COVID-19 pandemic. West Virginia increased 
reimbursement rates for certain SUD providers by 20%.117 California encouraged its Medicaid 
Exhibit 19. June 2020 National Council for 
Behavioral Health survey of community 
behavioral health organizations
  71% have had to cancel, reschedule, 
or turn away patients in the past three 
months.
  More than half do not have enough or 
are unsure whether they have enough 
PPE for the next two months.
  44% think they can survive six months 
or less in the current environment.
  On average, organizations have lost 
24.3% of their revenue during the 
COVID-19 pandemic.
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managed care plans charged with providing behavioral health benefits to issue monthly 
payments to SUD providers based on what they received last year, even as visit volume 
declined due to COVID-19.118 Finally, Washington instructed its MCOs to release funds to assist 
at-risk behavioral health providers through strategies such as advance payments, capitated 
contracts, and other options.119
Additionally, state insurance regulators can facilitate insurer support for providers whose 
business volume is down by reducing administrative barriers, such as prior authorization, and 
by directly supporting insurers whose revenues are down during the pandemic. For example, 
New York required insurers to develop plans for supporting providers with the savings insurers 
accrued from deferred services.
With the pressure on providers generated by COVID-19, some states took quick action to step 
up their monitoring of SUD provider capacity. For example, Virginia established an internal 
dashboard to gather data on where SUD providers (and other key/vulnerable provider types) 
were shutting down sites or clinics and when they intended to come back online or whether 
they intended to close, providing actionable data that has enabled the state to respond 
accordingly.
RECOMMENDATION: States, Medicaid managed care organizations, and 
commercial insurers should provide technical assistance and, where feasible, 
advance payments to SUD providers to sustain SUD networks during the 
COVID-19 pandemic.
E. Leverage telehealth to improve access
The rapid expansion of telehealth during the COVID-19 pandemic offers another opportunity 
to expand access on a permanent basis, particularly for providers who treat patients with OUD 
and SUD. A recent AAAP survey120 found that 80% of waivered physicians, physician assistants, 
and nurse practitioners who treat patients with OUD want virtual visits and other telehealth 
options to continue after the COVID-19 PHE ends, and 76% of providers perceived that their 
patients were satisfied with virtual visits to maintain medications for OUD. While telehealth 
access should not be viewed as a substitute for having an adequate in-person provider 
network, the changes made by the Drug Enforcement Administration (DEA) and SAMHSA 
to help individuals maintain access to critical services while adhering to social distancing 
recommendations and stay-at-home orders should be continued.
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Both Medicaid officials and insurance regulators expanded access to services through 
telehealth across multiple domains:
  Treatment and recovery services. Most states have issued Medicaid guidance related 
to MOUD telehealth services. Virginia’s Department of Medical Assistance Services 
allowed the counseling component of MOUD to be provided via telehealth or telephone 
communication.121 In addition, Florida required managed care plans to reimburse behavioral 
health providers for certain services (including MOUD) when provided via telemedicine (live, 
two-way communication).122
  Location. In response to the Public Health Emergency (PHE), most states123 are allowing 
both fee-for-service and managed care Medicaid beneficiaries to access services from their 
home, permitting the home to be an “originating site” for patients, rather than requiring 
that patients be within a provider’s office, hospital, or other health care facility to receive 
teleservices. For example, in Iowa, OTPs providing buprenorphine treatment are permitted 
to render services in the member’s home via telecommunication, telehealth, smartphone 
videoconference, or other electronic means.124
  Payment parity. New Hampshire explicitly provided payment parity for telehealth visits via 
HB 1623,125 and Oregon permitted providers to be reimbursed at the in-person rate for using 
telephone communications when barriers to equipment and access exist.126 The Centers for 
Medicare & Medicaid Services (CMS) issued guidance127 clarifying that “no federal approval 
is needed for state Medicaid programs to reimburse providers for telehealth services in the 
same manner or at the same rate that states pay for face-to-face services.”
  Technology platforms
 – Common video technologies such as FaceTime, Skype, and Zoom. The Office for 
Civil Rights (OCR) waived128 all provisions of the Health Insurance Portability And 
Accountability Act (HIPAA) privacy, security, and breach notification rules if a telehealth 
provider acted in good faith in attempting to comply with the guidance during the 
PHE. This has meant, for example, that a provider need not use a communications 
technology that complies with the HIPAA security rule, but instead can use other 
technologies—such as Zoom, FaceTime, or Skype—that might not meet all HIPAA 
requirements but are nevertheless designed to be non-public facing.
 – Audio-only telehealth. Many state Medicaid agencies followed Medicare’s lead to 
expand telehealth coverage to audio-only. This includes states that are either adding 
coverage for telephonic evaluation and management codes or allowing providers to 
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bill the usual service codes when the services are delivered via telephone (with certain 
parameters in place).129 As of October 1, all 50 state Medicaid agencies and Washington 
DC had issued guidance to allow for a form of audio-only telehealth services.
Enhancing provider capacity through telehealth training. Telehealth/telephone 
flexibilities are also a critical tool for maximizing existing specialty behavioral health and 
office-based opioid treatment workforces. For example, New Mexico’s TeleECHO (Extension 
for Community Healthcare 
Outcomes)130 programs are 
guided-practice models that use 
a hub-and-spoke knowledge-
sharing approach to improve 
provider capacity in rural and 
underserved areas. Programs 
encompass a wide range of 
trainings, including programs 
that aim to expand MOUD 
prescribing in primary care settings through virtual clinic training. The curriculum covers key 
aspects of prescribing (eg, overview of OUD and MOUD, induction, specifics of dosing, MOUD 
and co-occurring disorders, MOUD with special populations, etc), psychosocial supports 
(motivational interviewing, harm reduction, co-occurring disorders, etc), and clinic-level 
resources/skills (screening, monitoring, workforce staffing, billing, etc).
RECOMMENDATION: States should work with physician and other health 
care providers to evaluate the impact of telehealth expansions on patient 
access to MH/SUD treatment, and further support those expansions that 
prove effective beyond the pandemic. Such evaluations should emphasize 
the importance of continuity of care for MH/SUD patients by ensuring that 
all network providers have the option of providing telehealth services to 
their patients, and patients are not directed or incented to seek care from a 
separate telehealth network.
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V. Improve access to multidisciplinary, 
multimodal care for patients with pain
Administrative practices and payment 
structures put in place by payers create 
some of the most significant barriers for 
physicians seeking to provide comprehensive, 
multidisciplinary, multimodal pain care. Prior 
authorization requirements by payers are 
particularly burdensome for physicians and 
their staff. In fact, 92% of pain specialists 
surveyed in 2019 by the American Board 
of Pain Medicine reported that they were 
required to submit a prior authorization 
for non-opioid pain care, which delayed 
patient treatment, and 66% hired additional 
staff to process the greater administrative 
workload.131 Treatments shown to provide 
benefit for chronic pain but commonly 
subject to prior authorization include manual manipulation (ie, occupational or physical 
therapy), non-opioid prescription pain medications or treatments, and pain creams and 
patches.132 Another barrier is “fail first,” whereby payers cover the least costly medication or 
treatment first instead of what was recommended by the patient’s clinician. Variation in benefit 
plans means that pain services and medications are covered for some but not others.133
Payer coverage models vary widely and increase the complexity of prescribing treatment 
and the difficulty of accessing care. For example, there is clear evidence that integrated, 
multidisciplinary, and multimodal care results in better overall outcomes for chronic pain and 
is more cost effective in the long term than opioid therapy alone.134,135 Nevertheless, coverage 
of and payment for this type of pain care are inadequate. Benefit plans that don’t support 
multidisciplinary, multimodal, and collaborative care for pain are out of step with many clinical 
practices, current and emerging evidence, and the needs of patients with complex pain. The 
AMA endorses the US Department of Health and Human Services (HHS) Pain Management Best 
Practices Inter-Agency Task Force recommendations that payers remove barriers of inadequate 
coverage and inadequate reimbursement of treatments for chronic pain.
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A. Promote multimodal and multidisciplinary approaches to acute and 
chronic pain care to shift the paradigm for pain care
Multimodal pain care means the use of multiple types of treatments to treat the physical and 
psychological aspects of pain. Attitudes and assumptions on the appropriate response for 
treatment of pain has focused on pharmaceutical options to the detriment of other treatments 
for far too long. This understanding must change in order to support both patients and 
physicians in creating pain management plans and treatment regimens that produce better 
outcomes for patients. Physicians and other health care professionals are challenged to provide 
this individualized care due to large gaps in coverage for pain management treatments, from 
acupuncture and massage to non-opioid pharmaceuticals used for pain relief. This is not in 
alignment with recommendations from HHS’ Pain Management Best Practices Inter-Agency 
Task Force, which state that patient-centered and individualized plans of care are central to 
effective pain management.136
The AMA Opioid Task Force and the AMA Pain Care Task Force support increased research and 
access to multimodal, evidence-based treatment, including:
  Medication, including non-opioid pain relievers, anticonvulsants, antidepressants, 
musculoskeletal agents, anxiolytics, and opioid analgesics, when appropriate
  Restorative therapies, which include physical therapy, occupational therapy, physiotherapy, 
therapeutic exercise, osteopathic manipulative therapy (OMT), and other modalities such as 
massage and therapeutic ultrasound
  Interventional procedures, such as neuromodulation, radiofrequency ablation, peripheral 
nerve stimulation, central and peripheral nerve ablation, spine surgery, and steroid 
injections, and other emerging interventional therapies as part of the multimodal pain 
care plan
Several pain medicine physicians at top academic medical 
centers across the nation recently published “Pain Management 
Best Practices from Multispecialty Organizations during the 
COVID-19 Pandemic and Public Health Crises” to provide a 
framework for supporting pain management services, and 
noted that “systems-wide and individual decisions [on pain 
management] must take into account clinical considerations, 
regional health conditions, government and hospital directives, 
resource availability, [and] the welfare of health care providers.”137
2020 National Roadmap | 52
Physicians should be given access to all of the above as tools to create patient-centered, 
multimodal pain care plans that are not hindered by administrative or coverage barriers, 
ensuring that patients with acute or chronic pain have a wide range of options so that 
providers can personalize and tailor appropriate treatment plans to address their patients’ 
unique needs.
Multimodal care for acute pain. Multimodal pain care should be considered for acute pain 
(including postoperative pain) in place of relying on opioids or non-opioid pharmaceuticals 
alone. The evidence on which treatments are most effective by type of pain varies, but there 
is some promising evidence for treatment of musculoskeletal pain. The Agency for Healthcare 
Research and Quality (AHRQ) has assessed nonpharmacologic interventions for low back pain, 
and results indicate that interventions 
such as exercise therapy for acute and 
chronic pain caused by musculoskeletal 
conditions may offer relief while avoiding 
the risks of opioid therapy.138 However, 
coverage of rehabilitative therapies 
typically costs patients more (comparing 
the copay per physical therapy session 
versus the one-time copayment for 
a prescription drug), and such therapies 
are not always covered.
Medical efficacy of nonpharmacological pain therapies. Evidence supports the use of 
nonpharmacological restorative therapies, including physical therapy, occupational therapy, 
and acupuncture, as effective treatments for patients with pain.
  Physical therapy is commonly used to treat functional and/or musculoskeletal pain and 
aims to increase mobility, decrease pain, and improve functional and psychological status. 
A 2018 study that examined nearly 89,000 patients who visited a health care provider for 
either back, knee, shoulder, or neck pain found that those with knee pain who received early 
physical therapy were 66% less likely to fill a long-term opioid prescription (for 120 days 
or more), and patients with low back pain (LBP) who received early physical therapy were 
34% less likely to become long-term opioid users.139 Physical therapy provides the patient 
a minimally invasive option as part of a treatment plan.140 These components are critical in 
treating biomechanical and structural causes of pain and in addressing the psychological 
and behavioral components of pain through lower-risk options than prescription opioids. 
Numerous studies highlight physical therapy as an important component to sustained 
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recovery for patients with LBP and other musculoskeletal pain diagnoses, and extensive 
literature reviews show that “physical therapy only or added to usual care implies improved 
health in almost all studies.”141
  Because of their training in psychosocial interventions, occupational therapists help provide 
evidence-based, nonpharmacological interventions for treating acute and chronic pain.142 
Similar to physical therapy, occupational therapy is recognized as being efficacious for 
patients with pain because of patients’ active participation and ownership of the treatment 
(by continuing the therapy outside of regularly scheduled sessions). In addition, pain care 
from multiple alternative sources may work together to lessen pain in a way that no one 
type of therapy or medication can effectively address alone.
  Acupuncture is an evidence-based, cost-effective, and low-risk treatment option for 
numerous pain conditions, including chronic LBP, headache, chemotherapy-induced nausea 
and vomiting, knee osteoarthritis, migraines, postoperative nausea and vomiting, and 
postoperative pain.143
Multidisciplinary care for chronic pain. A multidisciplinary approach, involving providers 
such as pain management specialists, behavioral health interventionists, physical and 
occupational therapists, and primary care physicians (PCPs) is appropriate for individuals 
living with chronic pain. Treatment of chronic pain is a complex “sensory and emotional 
experience,” and it should include behavioral approaches to address the psychological, 
cognitive, emotional, behavioral, and social aspects of chronic pain. Focusing on appropriately 
meeting the behavioral health needs of chronic pain patients can have a significant impact on 
treatment outcomes.
Interdisciplinary pain management 
programs. Pain management 
specialists suggest that the best 
approach to functional improvement 
for people with significant, high-
impact pain or multiple health 
conditions is an interdisciplinary, 
coordinated pain management 
program that teaches patients how 
to (1) improve their physical function, 
(2) address stress and trauma that may 
lie at the root of the pain experience, 
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and (3) access services that may provide temporary pain relief. The goal of treatment is not to 
eliminate all pain, but to make pain manageable and to improve quality of life and the patient’s 
ability to conduct activities of daily living. Several examples of robust, interdisciplinary pain 
management programs include:
  The Swedish Hospital System’s Structured 
Functional Restoration Program (SFRP). 
This program, out of the Swedish Hospital 
System in Seattle, Washington, refers to 
itself as a “pain boot camp” and involves the 
coordination of care by a number of pain 
specialists and providers. The interdisciplinary 
team model has patients participating in four 
to five hour-long sessions, two to three times 
per week. During each session, patients visit 
with multiple pain providers and educators, 
sometimes individually and other times 
in groups.144
  Veterans Affairs’ Interdisciplinary Pain Rehabilitation Program. The VA’s 
Interdisciplinary Pain Rehabilitation Program focuses on restoring function and improving 
symptom self-management and quality of life. The main goal is to improve physical 
functioning with some, though less, emphasis on reducing pain severity. Individuals 
participate in the program for up to three months, attending weekly four hour-long 
sessions with a core team that includes themselves, family members or a support person 
(if appropriate), a pain physician, a pain psychologist, a physical therapist or rehabilitation 
specialist, and other professionals according to the individual’s needs.145
While these programs are good models for chronic pain management, most patients cannot 
access interdisciplinary, coordinated pain management programs because they are not 
widely available.
RECOMMENDATION: States should partner with universities, MCOs, health 
systems, and other stakeholders to identify, promote and meaningfully 
support increased access to evidence-based interdisciplinary pain 
management delivery models.
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B. Operationalize the multimodal approach to provide coverage through 
formularies and medical benefits
A more detailed regulatory review of formulary and benefit design by payers and PBMs is 
necessary to ensure that patients have affordable, timely access to evidence-based non-opioid 
alternatives, including both pharmacologic and nonpharmacologic options. In conducting 
such reviews, policymakers are urged to work closely with physicians to ensure appropriate 
clinical input.
Medicaid coverage for nonpharmacologic pain management modalities is mixed. While 
most states cover physical and occupational therapy, 20% of states do not; even when these 
therapies are covered, there are frequently limits on services. Chiropractic care is covered in 
only half of the states (see Exhibit 20 below).146,147
Exhibit 20. Coverage of nonpharmacologic therapies reported by state Medicaid agencies
Colorado law could become a national model. The Colorado Legislature approved a 
promising pain care bill in June 2020 that could become the foundation for a national model 
offering patients and their providers more options for dealing with pain than are typically 
available under health insurance benefit plans. HB 20-1085, which enjoyed broad bipartisan 
support, would have required insurers to cover up to six visits annually for physical therapy, 
occupational therapy, chiropractic services, and acupuncture, as well as reduce cost sharing 
and utilization management barriers to atypical opioids, which often are unaffordable for 
patients with pain despite compelling reasons to favor non-opioid alternatives when treating 
pain. The AMA joined the Colorado Medical Society, Colorado Consortium Against Prescription 
Drug Abuse, and dozens of stakeholders in support of the bill before Colorado Governor Jared 
Polis vetoed the bill, citing cost concerns.
Providing such coverage to patients in Colorado, including increased alternatives to opioids 
(ALTO) as part of a full continuum of treatment options, would have helped save money and 
improve patient care, according to a report and actuarial analysis148 submitted to the Colorado 
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Division of Insurance by the AMA, Colorado Medical Society, Colorado Pain Society, and Manatt 
Health. The report was in response to a DOI request for information to address Governor Polis’s 
concerns about whether another bill similar to HB 20-1085149 could be shown to provide access 
to cost-effective, evidence-based ALTOs for patients with pain.
The organizations consulted with pain medicine specialists in Colorado to show that ALTOs 
provide clear health benefits, and worked with Oliver Wyman Actuarial Consulting, Inc, on a 
preliminary set of actuarial analyses that show ALTOs also would save money on certain other 
health services. The analysis reinforces the need for a multimodal approach to treatment of 
pain that requires a critical review of administrative and other health insurance benefit barriers, 
exclusions, and exceptions to coverage that both inhibit the use of ALTOs and fail to address 
the needs of patients with acute or chronic pain, including populations that may benefit from 
opioid therapy when indicated. Key findings include:
  Oliver Wyman found that 13% of patients treated for pain incurred more than $2,500 per 
person in pain-related claims in 2018, and that these individuals had total health care costs 
roughly eight times the total health care costs of all remaining insured members.
  While opioid prescriptions have been significantly reduced in Colorado,150 the standard 
health insurance benefit plan continues to feature opioids as the most affordable treatment 
option for patients, while imposing barriers to ALTOs.
  Oliver Wyman’s analysis found that among patients with more than $2,500 in pain-related 
claims in 2018, certain other services, such as emergency department utilization, imaging, 
injections, and other procedures, were used less by patients who received the ALTOs 
proposed by HB 20-1085 compared with those who did not.
  Cost sharing and utilization management protocols required by health insurers for ALTOs 
were considerably more burdensome and more prevalent than those for opioid analgesics.
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The analysis also highlighted that while 
physical therapy, occupational therapy, and 
chiropractic services are currently covered 
for non-grandfathered individual and small 
groups in some form under the current 
Essential Health Benefit (EHB) benchmark 
plan in Colorado, they come with a number 
of significant exclusions/exceptions to 
coverage that do not address the needs 
of patients with acute or chronic pain. In 
addition, acupuncture, another low-risk and cost-effective therapy for a multitude of patients 
with pain, is not required to be covered for any health conditions under the Colorado EHB. 
Providing coverage for the proposed coverage benefits outlined in HB 20-1085 would expand 
cost-beneficial, effective treatment options to help patients with pain in Colorado.
The report also identifies other barriers that cannot be quantified in an actuarial analysis but 
are very real for patients. These barriers involve the social determinants of health, as well 
as potential inequities in how pain care has been provided—for example, a patient who 
would prefer to receive one of the ALTO nonpharmacologic options but is not able to take 
time off work, or a patient who cannot see a provider before or after work because of child 
care responsibilities or transportation limitations. These realities point to the complexity of 
situations faced by patients and necessitate the availability of a wide range of treatments and 
therapies for patients with pain.
RECOMMENDATION: State insurance regulators should review formulary 
and benefit design options from health insurers to ensure that the 
treatments pain medicine physicians recommend are included on a 
formulary’s lowest cost-sharing tier with low or no cost sharing.
RECOMMENDATION: States should ensure that policies seeking to increase 
the use of alternatives to opioids (ALTOs) take into account both coverage 
for ALTO treatments and meaningful access to those treatments, especially 
in cases where lack of housing or other social determinants of health create 
additional obstacles.
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C. Revisit policies that simply restrict opioid prescriptions
The federal government and states took aggressive action against the over-prescribing 
of opioids between 2016 and 2018, adopting 527 federal and state opioid-related policies 
(statutes, rules/regulations, and guidelines).151 Of these policies, 246 focused on Prescription 
Drug Monitoring Programs (PDMPs), and “170 specifically imposed limits on opioid prescribing 
and an additional 35 specifically referred to, or incorporated, the CDC opioid prescribing 
guideline.” Nearly every state also “mandated some amount of pain or opioid prescribing” 
continuing medical education (CME).
These laws have predictably reduced opioid prescriptions, but there is no indication that they 
have improved patients’ pain outcomes. For example, a 2020 AMA report found:152
  Opioid prescribing decreased for the sixth year in a row. Between 2013 and 2019, the 
number of opioid prescriptions decreased by more than 90 million—a 37.1% decrease 
nationally.153
  PDMP registrations and use continue to increase. In 2019, health care professionals 
nationwide accessed state PDMPs more than 739 million times—a 64.4% increase from 
2018 and an increase of more than 1,100% from 2014. More than 1.8 million physicians and 
other health care professionals are registered to use state PDMPs.154
Furthermore, these laws have had unintended consequences that need to be evaluated so that 
public policy can be recalibrated to ensure effective pain care. For example, these laws have 
led to a plethora of nonlegislative and nonregulatory actions that have treated CDC guidelines 
as a hard policy threshold when that is not their intent:
  Walmart’s policy includes a 50 MME or seven-day hard threshold for opioid prescribing.155
  CVS Caremark’s policy has multiple restrictions, including a seven-day hard threshold for 
opioid prescribing.156
  OptumRx’s policy is aligned with 2016 guidelines.157
  Walgreen’s Good Faith Dispensing Policy does not list specific thresholds, but the AMA has 
received numerous complaints about pharmacists refusing to fill a prescription because of 
“corporate policy.”158
  Blue Cross Blue Shield Association imposes a seven-day hard threshold.159
  UnitedHealthcare has a seven-day, 90 MME hard threshold.160
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Exhibit 21. CDC addresses Guideline’s misuse
The CDC has highlighted161 four specific ways in which 2016 Guideline for 
Prescribing Opioids for Chronic Pain has been misapplied:
  Misapplication of recommendations to populations outside of the Guideline’s 
scope. The Guideline is intended for primary care clinicians treating chronic pain for 
patients ages 18 and older. Examples of misapplication include applying the Guideline 
to patients in active cancer treatment, patients experiencing acute sickle cell crises, or 
patients experiencing postsurgical pain.
  Misapplication of the Guideline’s dosage recommendation that results in 
hard limits or “cutting off” of opioids. The Guideline states, “When opioids are 
started, clinicians should prescribe the lowest effective dosage. Clinicians should … 
avoid increasing dosage to ≥90 MME/day or carefully justify a decision to titrate dosage 
to ≥90 MME/day.” The recommendation statement does not suggest discontinuation 
of opioids already prescribed at higher dosages.
  The Guideline does not support abrupt tapering or sudden discontinuation of 
opioids. These practices can result in severe opioid withdrawal symptoms, including 
pain and psychological distress, and some patients might seek other sources of 
opioids. In addition, policies that mandate hard limits conflict with the Guideline’s 
emphasis on individualized assessment of the benefits and risks of opioids given the 
specific circumstances and unique needs of each patient.
  Misapplication of the Guideline’s dosage recommendation with respect to 
patients receiving or starting medication-assisted treatment for opioid use 
disorder. The Guideline’s recommendation about dosage applies to use of opioids in 
the management of chronic pain, not to the use of medication-assisted treatment for 
opioid use disorder. The Guideline strongly recommends offering medication-assisted 
treatment for patients with OUD.
In addition, these laws have not been counterbalanced by any meaningful increase in access 
to ALTOs or reductions in administrative barriers. Health insurance companies continue to 
delay and deny access to non-opioid pain care and evidence-based treatment for opioid use 
disorder, while pharmacy chains, pharmacy benefit managers, and state laws continue to 
inappropriately use arbitrary guidelines to restrict access to legitimate medication that some 
patients need to help manage their pain.
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Exhibit 22. Pain specialists face treatment barriers
  92% of pain medicine specialists said that they have been required to submit a prior 
authorization request for non-opioid pain care. Physicians and their staff spend hours 
per day on such requests.
  72% of pain medicine specialists said that they—or their patients—have been 
required to reduce the quantity or dosage of medication prescribed.162
In sum, the data show that physicians have taken considerable steps—before and after policy 
mandates—to reduce opioid prescriptions and to use PDMPs. Yet it is not clear that these 
restrictive laws have led to reduced drug-related mortality or improved access to evidence-
based pain care. There is, however, growing evidence that arbitrary opioid restriction policies—
including the CDC’s failure to clarify that its 2016 Guideline should not be used as a hard 
threshold—have harmed many patients.163,164
RECOMMENDATION: States with prescription opioid restriction policies, 
PDMP requirements, or CME mandates should undertake a retrospective 
review, including qualitative interviews with physicians and patients with 
pain to determine the impact of these policies, including patient outcomes. 
If policies based on the 2016 CDC Guideline are not found to have improved 
patient outcomes, the policies should be revised or rescinded.
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VI. Expand harm reduction efforts to reduce 
death and disease
Harm reduction seeks to minimize the negative impacts associated with drug use and is 
an essential component of addressing the drug overdose epidemic. In 2019, a nationwide 
network of harm reduction organizations distributed more than 1 million doses of naloxone.165 
Without the widespread availability and distribution of naloxone from community-based harm 
reduction organizations, hundreds of thousands of overdose events likely would have ended 
in death. Given the importance and efficacy of naloxone, it’s critical to ensure people who use 
drugs, those with an OUT and their family members and loved ones have sufficient access to 
naloxone. This section examines the challenge of providing that access and looks at broader 
harm-reduction policies, such as syringe service programs (SSPs) and targeted messaging, that 
states are increasingly implementing to prevent overdoses, especially during the COVID-19 
pandemic.
A cornerstone of states’ approaches 
to harm reduction is the availability of 
naloxone, the opioid overdose-reversal 
agent. According to the American Society 
of Addiction Medicine, “[n]aloxone is a 
remarkably effective, inexpensive, and 
safe medication. It acts quickly, and 
has no addictive potential.”166 The US 
surgeon general has also emphasized 
the importance of naloxone to save lives 
from opioid-related overdose.167 Equally 
important is the availability of SSPs.
Harm reduction should also include 
broader efforts to prevent harm, such as 
syringe services programs (SSPs). In addition to providing sterile needles and syringes to help 
reduce blood-borne infections, SSPs distributed more than 700,000 doses of naloxone, including 
refills, during a 12-month study period that captured the responses of 263 SSPs nationwide.168 
The study also found that more than 25% of respondent SSPs distributed naloxone to more than 
1,000 persons in the past 12 months, and 29% of SSPs “ran out of naloxone or needed to ration 
their naloxone in the preceding 3 months.” Naloxone distribution varied by region.
A cornerstone of states’ approaches 
to harm reduction is the availability 
of naloxone, the opioid overdose-
reversal agent. According to the 
American Society of Addiction 
Medicine, “[n]aloxone is a remarkably 
effective, inexpensive, and safe 
medication. It acts quickly, and has no 
addictive potential.” The US surgeon 
general has also emphasized the 
importance of naloxone to save lives 
from opioid-related overdose. Equally 
important is the availability of sterile 
needle and syringe services programs.
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A. Continue to expand access to naloxone programs
All 50 states and the District of Columbia have enacted laws to support broad, unrestricted 
access to naloxone. This includes provisions to enable people to obtain naloxone directly 
from a pharmacist without a patient-specific prescription—referred to as a “standing order” 
authorization. In response to COVID-19, a number of states have taken even more steps to 
get naloxone into the hands of individuals at risk of overdose, their family members, and first 
responders. The AMA Opioid Task Force also recommends the provision of naloxone in a wide 
range of settings, including primary care settings, specialty care settings, and emergency 
departments to patients at risk of overdose.
Prescribing naloxone to those at risk of overdose. The AMA Opioid Task Force recommends 
that the decision to prescribe naloxone should remain within the purview of the patient and 
the physician. According to HHS, through increased prescribing and standing orders, naloxone 
prescriptions increased from 136,395 to nearly 600,000 between 2016 and 2018;169 however, 
national data on patients to whom clinicians should consider prescribing naloxone show that 
less than 1% of these patients actually receive a naloxone prescription.170 Data for 2019 shows 
more than 1 million naloxone prescriptions were dispensed.171
Increasing access also requires removing barriers. Barriers persist to ensuring patients who 
would benefit from naloxone can receive it. While pharmacies in nearly every state have the 
authority to dispense naloxone to patients without a patient-specific prescription, pharmacists 
report many barriers to doing so. This includes lack of time to educate patients, insufficient 
support from corporate managers, and a lack of pharmacist education and training.172 Thus, 
while some national pharmacy chains have signaled strong support for naloxone education 
and distribution,173,174 more work needs to be done to ensure that patients and others can 
readily access naloxone from their pharmacy.
Another key barrier is cost. A CDC study175 found that in 2018, 
only 42% of naloxone prescriptions dispensed at a pharmacy 
“did not require out-of-pocket costs.” For the remaining 
naloxone prescriptions:
  24.5% required out-of-pocket (OOP) costs of less than $10
  21.9% required OOP costs between $10.01 and $50
  5.8% required OOP costs of more than $50
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The CDC found that Medicare required OOP costs for 71% of naloxone prescriptions, and 
Medicaid and commercial insurance required OOP costs 44% and 41% of the time, respectively. 
It is not clear how often these OOP costs prevented individuals from obtaining naloxone.
Several states have implemented low- or no-cost naloxone availability programs to increase 
patient access, especially during the COVID-19 pandemic. These include:
  An ongoing policy in New York176 that provides naloxone at no cost through registered 
opioid overdose prevention programs and state copayment assistance of up to $40 
for naloxone
  Programs by the New Jersey Harm Reduction Coalition,177 including a program that 
prioritizes free naloxone distribution for people who use drugs, people who have recently 
stopped using drugs, people returning home after incarceration, people leaving treatment, 
and their families, partners, friends, and roommates; and a program that enables individuals 
to receive naloxone through the mail after completing a brief online training and a 
request form
  Programs by the Ohio Harm Reduction Coalition,178 including a mail-based Narcan and 
naloxone distribution program that provides free Narcan to Ohio residents who think they 
may be in a position to reverse an overdose during the COVID-19 pandemic; and Project 
DAWN (Deaths Avoided With Naloxone), Ohio’s network of opioid education and naloxone 
distribution programs, which provides program participants with a take-home naloxone kit 
and educational training
  In Massachusetts, an initiative by the Winthrop Police Department179 to offer survival kits 
to prevent overdoses and connect individuals to recovery resources during the COVID-19 
pandemic that include naloxone; local resources to facilitate referrals to detoxification 
services, harm reduction services, MOUD, and recovery supports; COVID-19 safety 
information; and fentanyl safety information and, in some cases, testing strips
  Statewide naloxone distribution days in Pennsylvania,180 which provided free naloxone at 95 
locations (including state health centers and county/municipal health departments) to any 
Pennsylvanian who wanted it as part of the administration’s ongoing effort to reduce opioid 
overdoses and get residents into treatment
  In Maine, shortly following her inauguration, Governor Janet T. Mills signed Executive Order 
#2 which authorized purchase and distribution of 35,000 doses of naloxone. Distributed 
through the Maine Naloxone Distribution Initiative, the medication was made available 
to any individual requesting it, although insured patients were encouraged to obtain a 
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prescription in order to obtain third party payment. Medicaid also covers naloxone without 
prior authorization. Over a fifteen-month period, the state purchased naloxone has been 
tracked and was responsible for 935 successful reversals.
In terms of cost, legislation can address cost-sharing barriers, and regulators can ensure that 
naloxone is not placed on prohibitively high cost-sharing tiers of health insurers’ pharmacy 
benefits. Additionally, policymakers can and should ensure that other payer-imposed 
administrative barriers, such as prior authorization, are not delaying patients’ access to 
naloxone and deterring individuals from filling prescriptions at the pharmacy counter. For 
example, states such as Colorado provide access to naloxone without prior authorization under 
Medicaid. This practice should be extended to commercial payers and adopted in every state.
Finally, life insurers may be adding to the barriers imposed by health insurers by inquiring 
about naloxone use in life insurance applications. The Colorado Division of Insurance issued 
a bulletin on January 31, 2020, explicitly prohibiting an insurer from denying insurance on the 
basis of an applicant’s naloxone use:181 “[A]n insurer cannot utilize information regarding the 
purchase of naloxone as part of evaluation of an application for insurance.” We recommend all 
states issue similarly clear guidelines.
RECOMMENDATION: States should increase access to naloxone by removing 
cost-sharing and administrative barriers for individuals seeking a 
prescription for naloxone for themselves or a family member or loved 
one; promoting and encouraging health care professionals to prescribe 
naloxone to patients who may be at risk of overdose—or their family 
members or friends; and supporting community-based harm reduction 
organizations in distributing no-cost naloxone in the community.
B. Pursue comprehensive harm reduction efforts
Life-saving harm reduction efforts extend far beyond the prescribing of naloxone. Especially in 
the midst of the COVID-19 pandemic, in which access to outpatient and inpatient rehabilitation 
and treatment centers has become notably more difficult182 and feelings of isolation are on the 
rise, extending comprehensive harm reduction efforts across states is essential to ensuring care 
continuity and support at a time that is especially challenging for individuals with a substance 
use disorder. Broader harm reduction strategies include syringe services programs, pharmacy 
distribution of clean syringes, and new ways to target communication about safe practices.
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Syringe services programs. Syringe services programs are community-based prevention 
programs that provide access to and disposal of sterile syringes and injection equipment. The 
CDC points out the numerous benefits of SSPs,183 including reducing the risk of blood-borne 
infection, preventing outbreaks, and preventing viral hepatitis, HIV, endocarditis, and other 
serious health issues. These programs are increasingly being recognized as effective and safe 
harm reduction strategies to support individuals with an SUD.
SSPs are beneficial not only because they 
protect the public and first responders by 
facilitating the safe disposal of used needles and 
syringes, but effective SSPs also reduce stigma 
and provide critical bridges for individuals with 
an SUD to other important health services, 
including hepatitis C and HIV diagnosis and 
treatment, as well as MOUD. According to the 
CDC, “people who inject drugs who regularly 
use an SSP are more than five times as likely to 
enter treatment for a substance use disorder, 
and nearly three times as likely to report reducing or discontinuing injection as those who have 
never used an SSP.”184 In addition, SSPs are uniquely positioned to provide culturally relevant 
services and provide outreach to persons at high risk for experiencing or observing an opioid 
overdose, and provide access to naloxone and educational information about treatment for 
SUDs. According to a 2020 study from the CDC, in 2019, 94% (n=247) of SSPs had implemented 
evidence-based overdose education and 
naloxone distribution programs, providing 
critical supports and services for individuals 
who visit SSPs.185
The COVID-19 pandemic has highlighted 
how SSPs are facing challenges in continuing 
operations, which puts individuals who 
rely on SSPs at risk. As part of its state 
recommendations concerning harm 
reduction,186 the AMA recommends that 
states ensure continuity of syringe services 
programs, including provision of PPE. This 
includes expanding PPE priority to include harm 
According to the CDC, people 
who inject drugs who regularly 
use an SSP are more than five 
times as likely to enter treatment 
for a substance use disorder, and 
nearly three times as likely to 
report reducing or discontinuing 
injection as those who have 
never used an SSP.
The AMA recommends that 
states ensure continuity of 
syringe services programs, 
including provision of PPE. This 
includes expanding PPE priority 
to include harm reduction 
organizations and other 
community-based organizations 
that provide services to people 
who inject drugs, to help protect 
against the spread of infectious 
disease.
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reduction organizations and other community-based organizations that provide services to 
people who inject drugs, to help protect against the spread of infectious disease.
The AMA also recommends that states implement, as part of an executive order or other 
initiative, specific policies to increase access to sterile needle and syringe exchange services. 
An executive order issued by Maine Governor Janet Mills as part of her pandemic response 
removed restrictions in the state on sterile needle and exchange services to help reduce harms 
among people who inject drugs and protect against the spread of infectious disease. Under 
Executive Order 27, the state will no longer require during the national COVID-19 PHE a 1:1 
exchange—allowing individuals to receive multiple sterile needles and exchanges.187 The Order 
also allows for the mailing of SSP supplies in order to minimize the need for social distancing at 
the SSP locations.
While Maine provides a good example, 11 states still do not have any formal SSP.188
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There also is a long-term need to ensure that individuals who work in SSPs, as well as those 
who obtain supplies from SSPs, are not subject to arrest or prosecution for providing sterile 
needle and syringe supplies. This includes providing or possessing sterile or used needles, 
hypodermic syringes, or other injection supplies obtained from or returned to a program, 
including testing supplies for illicit substances. It also includes residual amounts of a controlled 
substance contained in a used needle, used hypodermic syringe, or used injection supplies 
obtained from or returned to a program.189
Exhibit 24. California’s Pharmacy Access Bill
In late September, California Governor Newsom signed the Pharmacy Access Bill (AB 
2077)190 into law until January 1, 2026, which protects both pharmacists’ and providers’ 
discretion to provide hypodermic needles and syringes to individuals without a 
prescription, and an individual’s right to possess such syringes for personal use without 
fear of prosecution.191
Targeted messaging. During the COVID-19 pandemic, states and SUD treatment providers 
have released flyers and guidance to people who use drugs on how they can safely use drugs 
during the pandemic and access harm reduction resources. Rhode Island’s instructions include 
preventing overdose by having a friend check in, using one drug at a time and going slowly; 
stocking up on supplies such as naloxone, fentanyl testing strips, and clean syringes; trying to 
maintain social distancing with others; and trying not to share supplies.192
RECOMMENDATION: States should adopt laws and other policies to 
remove barriers to sterile needle and syringe exchange programs, including 
decriminalization of SSP supplies; and to ensure continuity of syringe 
services programs, including by expanding PPE priority to include harm 
reduction organizations and other community-based organizations that 
provide services to people who inject drugs to help protect against the 
spread of blood-borne infectious disease.
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VII. Improve monitoring and evaluation
Collaboration and sharing of timely data are critical for responding to the overdose epidemic 
our nation currently faces. According to the Bipartisan Policy Center, the federal government 
provided $7.6 billion in funding in 2019 for a variety of opioid-related efforts ranging from 
treatment, recovery, and prevention to research and law enforcement.193 This was a 3.2% 
increase from 2018, but as in previous years, the results of these efforts are unclear. Part 
of the reason is that there are insufficient data that can be used to help tailor meaningful 
intervention. With overdose deaths on the rise, we cannot let data collection delay action, 
but there are multiple areas for state-level improvement in collecting data as expeditiously 
as possible:
  Gather enhanced, standardized surveillance data of fatal and nonfatal overdose, including 
evidence of naloxone administration and referral to treatment.
  Increase data gathering to better address delivery of care by race, gender, age, ethnicity, 
income, and other factors that may point to inequitable distribution of care.
  Begin meaningful review of policies to help determine whether actions taken by state 
legislatures and state agencies have led to measurable impacts in reducing drug-related 
harms and improving access to care. Policies that have not helped should be revised 
or rescinded.
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A. Standardize data reporting
Standardized overdose surveillance data can be used to inform targeted drug-
related prevention, treatment, policymaking, and harm reduction strategies. However, 
implementation of data-sharing programs and subsequent data visualization are complex 
and suffer from a lack of data standardization and quality standards, disparate overdose 
surveillance case definitions, and lengthy delays in data acquisition. Currently, national 
surveillance efforts include fatal overdose data; however, relying on fatality data alone can 
result in an incomplete picture of the ongoing and evolving overdose epidemic.194 It is 
important to have data that show the evolution of the epidemic—from one driven primarily by 
nonmedical use of prescription opioids to one now fueled by illicitly manufactured fentanyl, 
fentanyl analogs, heroin, cocaine, and methamphetamine.195 While these data tell us that 
policy interventions must shift, the 
data do not tell us where to target 
comprehensive prevention and 
treatment efforts. Timely, nationally 
representative data related to 
nonfatal overdoses currently do 
not exist. Effectively implementing 
optimal policies, prevention 
strategies, and interventions 
will require coordination of 
stakeholders and accurate, timely, 
and actionable information on both 
fatal and nonfatal drug-related 
overdoses and interventions.
Need for consistency in nonfatal overdose reporting to inform public health 
interventions. All 50 states have a system for mandatory case reporting to health 
departments in a timely manner, allowing state health departments to track potential 
outbreaks and rising epidemics. However, most states do not have laws or policies that require 
timely reporting of drug overdoses or that recognize adverse drug reactions and overdoses 
as reportable conditions. What gets reported with respect to nonfatal overdoses varies 
considerably with respect to who is required to report, what information gets reported, to 
whom the information must be reported, and the time interval for reporting.196 Public health 
researchers have emphasized that “the provision of rapid, targeted interventions to overdose 
survivors as well as to that person’s friends and family members and highly affected areas may 
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be one of the best uses of scarce public health outreach resources. These interventions can 
be delivered by trained public health nurses, social workers, and peers in recovery as part of 
the health agency’s ongoing programming or as a rapid response team specifically created to 
address the overdose crisis.”197 The CDC similarly recommends that “[t]imely data help improve 
coordination among health departments, community members, healthcare providers, public 
health, law enforcement, and government agencies and promote readiness for regional 
or multiple state overdose increases.”198 Maine’s recently announced OPTIONS (Overdose 
Prevention Through Intensive Outreach, Naloxone and Safety) provides a behavioral health 
professional in each county to outreach to overdose survivors.
It also is critical to understand that the epidemic’s effects vary by race, gender, age, ethnicity, 
income, and other factors. Just as clinical treatment regimens must be informed by the unique 
characteristics of each individual, so too must policies be tailored and targeted to ensure 
equitable interventions. For example, policy interventions to address nonmedical use of 
prescription opioids by youth likely are going to be different than policies to increase access 
to treatment for those in their 40s or 50s who use illicit fentanyl. As a first step, it is essential 
to capture the data for fatal and nonfatal overdose by race, ethnicity, age, gender, geography, 
and income. It is further essential to understand those groups’ insurance status and whether 
they have sought and received treatment, including how much it has cost and whether the 
individuals have been subject to any utilization management protocols or other barriers, such 
as prior authorization or step therapy.
RECOMMENDATION: States should implement standardized systems 
to accurately monitor and evaluate overdose and mortality trends to 
provide equitable public health interventions that include comprehensive, 
disaggregated racial and ethnic data collection related to testing, 
hospitalization, and mortality associated with opioids and other substances.
RECOMMENDATION: States should require health insurance companies 
to report deidentified data on enrollees who have received treatment, 
length and type and cost of care (eg, residential, intensive outpatient, 
other outpatient), and whether those individuals have been required to go 
through any utilization management protocols as a condition of receiving 
treatment.
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B. Increase data surveillance and reporting
The CDC has implemented a new funding agreement, Overdose Data to Action (OD2A), that 
supports recipients in collecting in-depth data on drug overdoses, and in using those data 
to inform prevention and public health response efforts.199 Funded recipients include state, 
territorial, county, and city health departments. OD2A builds on previous programs, including 
the “Enhanced State Opioid Overdose Surveillance (ESOOS),” which CDC notes are to “provide 
more timely and comprehensive data on fatal and nonfatal opioid overdoses and risk factors 
associated with fatal overdoses.” ESOOS grants have helped create State Unintentional Drug 
Overdose Reporting Surveillance (SUDORS) systems in several states.200
Multiple states were awarded federal grants for their ESOOS and created SUDORS programs. 
Rhode Island, for example, enhanced its reporting on the factors identified above,201 but 
it is not clear how the comprehensive data are being widely used. Information from Iowa, 
Massachusetts, and Illinois suggest that the data are used across multiple agencies.202,203,204 
Promising efforts in Georgia and Ohio suggest that data showing spikes in overdose are 
transmitted to public health authorities to target interventions, but the extent to which 
these efforts have been statewide or led to long-term treatment is not clear.205 CDC staff has 
presented on multiple areas of promise for SUDORS-type programs, but it is similarly unclear 
how states will sustain them due to their reliance on federal funding.
Another example of a program where data are being used to target interventions is RxSafe 
Marin,206 a county-level, data-driven overdose prevention and education network that relies on 
data sharing and community-based engagement to bring together physicians, pharmacists, 
educators, law enforcement, and others in a broad-based effort. One example of its work 
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includes data-sharing agreements to help emergency medical technicians record when 
naloxone was administered to reverse an opioid overdose. The program effort led to weekly 
reports identifying where overdoses occurred and alerts if there were three or more overdoses 
in a day. The data-sharing agreements and county policies allow for follow-up contact with 
every patient who overdoses to link them with behavioral health services and treatment.
Another area of action has been the creation of dashboards to provide a snapshot of how the 
epidemic has impacted the state. Dashboards have been developed at regional, state, county, 
and community levels. Reviewing different dashboards, however, reveals wide differences in 
the types of data included, the types of data sources, frequency of data updates, and the data 
visualization methods used.207 Some states, such as Colorado,208 Florida,209 Maryland,210 and 
Vermont,211 and even more regional jurisdictions212 provide a wide range of information in their 
reports. For example, Colorado includes emergency department admissions, Florida highlights 
the use of PDMPs, and Vermont takes a scorecard-type approach. Each effort has merit and is 
likely the result of considerable resources, but on the surface, it is not clear how the different 
efforts positively affect timely surveillance or are linked to the broader health care and public 
health communities. The Georgia Department of Public Health, for example, has done an 
exemplary job of using syndromic surveillance to detail opioid-related harms throughout the 
state, including providing statewide updates during the COVID pandemic.213
RECOMMENDATION: States receiving federal grants to implement 
overdose-related action plans should be required to publicly report on the 
programs’ progress, including whether and how they have partnered with 
medical societies and other stakeholders to ensure that the data obtained 
are provided to health care and public health professionals. Programs 
also should be required to publicly report how the data have been used to 
implement overdose prevention, treatment, and recovery-related efforts 
in the state.
C. Monitor and evaluate policy
States must actively monitor and evaluate their policy and program initiatives to ensure that 
resources are being used efficiently and that interventions are effective in meeting their 
goals. Monitoring should include review of information on an immediate and ongoing basis 
to determine how an intervention is unfolding and whether policies should be adjusted to 
address unintended consequences. In some cases, midcourse corrections will be needed. 
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Evaluation should be done at set intervals, often at the midpoint and end of a demonstration 
program, or yearly for other types of interventions. Evaluation can help determine whether 
hypotheses about impacts are accurate and whether the related impacts can be attributed 
to the intervention after controlling for other independent factors, such as the COVID-19 
pandemic that has changed the landscape in many unexpected ways.214 While it appears that 
few states have initiated the kind of comprehensive policy reviews warranted by this epidemic, 
some state Medicaid agencies are monitoring and evaluating changes that have been 
implemented. COVID-19 has been an unexpected source of innovation, creating opportunities 
for states to assess and evaluate the impact of policies they adopted during the pandemic, to 
determine whether maintaining them in the long term is warranted.
  West Virginia. West Virginia has embedded in the Medicaid agency statisticians/data 
staff from West Virginia University who are helping to track the impact of policy changes 
adopted during the pandemic.
  Virginia. Virginia maintains a contract with Virginia Commonwealth University to evaluate 
the state’s approach to SUD treatment, including through qualitative research such as focus 
groups on the impact of moving to telehealth during the COVID-19 pandemic, and ongoing 
data analysis.
  Medicaid Outcomes Distributed Research Network (MODRN). Through MODRN, a group 
of state Medicaid agencies and partner universities adopt a common data model, contribute 
to a common analytic plan, and conduct analyses locally on their own Medicaid data using 
standardized code developed by a data coordinating center. Finally, the state-university 
partners provide aggregate results, not data, to the data coordinating center, which 
synthesizes the aggregate findings from multiple states for reporting. MODRN’s first project 
assessed OUD treatment quality and outcomes in Medicaid, working with nine states 
(Kentucky, Maryland, Michigan, North Carolina, Ohio, Pennsylvania, Virginia, West Virginia, 
and Wisconsin) to inform policy decisions on coverage of OUD treatments in Medicaid. 
MODRN analyzed 20 access, quality, and outcomes measures and found significant variation 
in the access to and quality of treatment for OUD across Medicaid programs.215
RECOMMENDATION: States should use federal and state data to assess 
the results of their SUD, pain, and harm-reduction policies to identify 
and expand successful programs and to make appropriate midcourse 
corrections where needed.
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VIII. Conclusion
This roadmap covers a lot of terrain and offers many recommendations 
for further action:
Policy enactment has been extensive. Policymakers and regulators across the country and 
in Washington, DC, have spent considerable time, energy and resources on ending the nation’s 
drug overdose epidemic. This epidemic has led to the passage of hundreds of new laws, 
regulations, clinical guidelines, and national recommendations. Some are evidence-based, such 
as increasing access to MOUD, enforcing mental health and substance use disorder parity laws 
and enhancing access to harm reduction services, including continued emphasis on access to 
naloxone to help save lives from opioid-related overdose.
Policy implementation remains elusive. 
Even as access to evidence-based treatment 
for OUD has been a major focus, much more 
work remains to ensure access to treatment 
for OUD. Putting policies into action requires 
additional steps, which is why the bulk of 
recommendations in this report focus on 
tangibly removing barriers to evidence-based 
treatment for OUD and enforcing state and 
federal parity laws. Health insurance companies 
and other payers must change their practices or 
patients will continue to be harmed.
Moreover, while some policymakers have recognized the need to increase access to 
alternatives to opioids, few actions have occurred to make access to ALTOs a reality. In addition, 
while naloxone has saved the lives of tens of thousands of Americans, comprehensive harm 
reduction efforts also must include increased access to sterile needle and syringe services 
programs.
Policies must be examined. This report highlights the need for thorough evaluation and 
commitment by states to further policies that work and to revise or rescind policies that are 
harmful to patients. This includes ensuring that policy evaluation and data collection directly 
address long-standing health inequities. Specifically, policies must be carefully examined to 
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determine whether they help improve patient outcomes and reduce mortality. If they don’t 
accomplish these goals, they need attention.
There are many examples to learn from. The AMA–Manatt analyses reveal multiple 
areas in which there have been positive outcomes and promising results. This includes the 
development of hub-and-spoke models of care, community-based naloxone access efforts, 
and reforms in state Medicaid agencies to improve access to multidisciplinary, multimodal pain 
care. The 2020 roadmap identifies many initiatives that all states can learn from and potentially 
adopt. This includes providing MOUD to those in justice-involved settings, removing stigma for 
OUD and pain, and using data to meaningfully reduce longstanding health inequities.
Demonstrating program success is a work in progress. This report identifies many areas 
in which additional work can be done to further increase access to evidence-based care, 
including pilot projects being done by emergency departments to assess and refer patients to 
treatment for OUD. Because many successful pilot programs are dependent on grant funding, 
we urge greater attention to program evaluation to help illuminate which pilot programs that 
may be helping hundreds of people today can be scaled up as national models that could help 
hundreds of thousands tomorrow.
All stakeholders can take action. This national roadmap provides recommendations 
that may not be easy to implement, but they are necessary to help end the epidemic. 
There are recommendations that can be applied by governors, state legislators, attorneys 
general, insurance commissioners, Medicaid officials and other policymakers. Many of the 
recommendations also could be implemented voluntarily by health insurance companies, 
PBMs and other stakeholders if they were so inclined or encouraged to do so. Patients with 
an SUD and patients 
with pain need help. The 
overdose epidemic is 
more deadly than ever. 
Physicians and other 
health care professionals 
must continue to take 
action, and the AMA 
stands ready to work 
with all stakeholders 
to implement these 
recommendations and 
help America’s patients.
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